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Abstract 
Transforming growth factor β1 (TGF-β1) is a cytokine that reportedly affects the severity of 
cystic fibrosis lung disease. The goal of this project was to define the effect of TGF-β1 on vas 
deferens, an organ that is universally affected in male cystic fibrosis patients.  
In the first study, experiments were conducted using freshly isolated porcine vas deferens 
epithelial cells. Primary porcine vas deferens epithelial cells exposed to TGF-β1 exhibited a 
significantly reduced basal transepithelial electrical resistance (Rte). TGF-β1-induced reduction 
in Rte was prevented by SB431542, a TGF-β receptor I inhibitor, indicating that the effect of 
TGF-β1 requires the activation of TGF-β receptor I. Western blot and immunohistochemistry 
results showed the expression of TGF-β receptor I in native vas deferens epithelia, indicating that 
the impaired barrier function and anion secretion that were observed in cultured vas deferens 
cells can likely be observed in the native context. Immunohistochemical outcomes showed that 
TGF-β1 exposure led to loss of organization of tight junction proteins occludin and claudin-7. 
These outcomes suggest that TGF-β1 impairs the barrier integrity of epithelial cells lining the vas 
deferens. 
In a parallel study that employed PVD9902 cells that are derived from porcine vas deferens, 
TGF-β1 exposure significantly reduced anion secretion stimulated by forskolin, forskolin/IBMX, 
and 8-pCPT-cAMP, suggesting that TGF-β1 affects downstream targets of the cAMP signaling 
pathway. Real-time RT-PCR and western blot analysis showed that TGF-β1 exposure reduced 
both the mRNA and the protein abundance of cystic fibrosis transmembrane conductance 
regulator (CFTR). Pharmacological studies showed that the inhibitory effect of TGF-β1 on 
forskolin-stimulated anion secretion was abrogated by SB431542 and attenuated by SB203580, a 
p38 mitogen-activated protein kinase (MAPK) inhibitor. These outcomes suggest that TGF-β1, 
via the activation of TGF-β receptor I and p38 MAPK signaling, reduces CFTR expression, and 
thus impairs CFTR-mediated anion secretion. 
Outcomes from these studies suggest that, in epithelial cells lining the vas deferens, TGF-β1 
exposure leads to an impaired physical barrier and/or reduced anion secretion, which is expected 
  
to modify the composition and the maintenance of the luminal environment and thus, is expected 
to reduce male fertility. 
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Transforming growth factor β1 (TGF-β1) is a cytokine that reportedly affects the severity of 
cystic fibrosis lung disease. The goal of this project was to define the effect of TGF-β1 on vas 
deferens, an organ that is universally affected in male cystic fibrosis patients.  
In the first study, experiments were conducted using freshly isolated porcine vas deferens 
epithelial cells. Primary porcine vas deferens epithelial cells exposed to TGF-β1 exhibited a 
significantly reduced basal transepithelial electrical resistance (Rte). TGF-β1-induced reduction 
in Rte was prevented by SB431542, a TGF-β receptor I inhibitor, indicating that the effect of 
TGF-β1 requires the activation of TGF-β receptor I. Western blot and immunohistochemistry 
results showed the expression of TGF-β receptor I in native vas deferens epithelia, indicating that 
the impaired barrier function and anion secretion that were observed in cultured vas deferens 
cells can likely be observed in the native context. Immunohistochemical outcomes showed that 
TGF-β1 exposure led to loss of organization of tight junction proteins occludin and claudin-7. 
These outcomes suggest that TGF-β1 impairs the barrier integrity of epithelial cells lining the vas 
deferens. 
In a parallel study that employed PVD9902 cells that are derived from porcine vas deferens, 
TGF-β1 exposure significantly reduced anion secretion stimulated by forskolin, forskolin/IBMX, 
and 8-pCPT-cAMP, suggesting that TGF-β1 affects downstream targets of the cAMP signaling 
pathway. Real-time RT-PCR and western blot analysis showed that TGF-β1 exposure reduced 
both the mRNA and the protein abundance of cystic fibrosis transmembrane conductance 
regulator (CFTR). Pharmacological studies showed that the inhibitory effect of TGF-β1 on 
forskolin-stimulated anion secretion was abrogated by SB431542 and attenuated by SB203580, a 
p38 mitogen-activated protein kinase (MAPK) inhibitor. These outcomes suggest that TGF-β1, 
via the activation of TGF-β receptor I and p38 MAPK signaling, reduces CFTR expression, and 
thus impairs CFTR-mediated anion secretion. 
Outcomes from these studies suggest that, in epithelial cells lining the vas deferens, TGF-β1 
exposure leads to an impaired physical barrier and/or reduced anion secretion, which is expected 
  
to modify the composition and the maintenance of the luminal environment and thus, is expected 
to reduce male fertility. 
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Chapter 1 - Introduction 
 Overview 
Cystic fibrosis is a recessive genetic disorder caused by mutations of the gene encoding the 
cystic fibrosis transmembrane conductance regulator (CFTR), a multifunctional membrane 
protein that regulates anion permeation. CFTR plays a role in the normal function of many 
biological systems and mutant CFTR forms are associated with pathology in many systems, 
including the respiratory, gastrointestinal, digestive, and reproductive systems. Cystic fibrosis 
affects the architecture of the vas deferens and thus induces male infertility. The severity of 
cystic fibrosis, especially cystic fibrosis lung disease, is not only mediated by the CFTR 
genotype, but also is affected by other factors such as transforming growth factor β1 (TGF-β1), a 
cytokine that is expressed in many organs and is present at a relatively high concentration in the 
male reproductive tract. 
The aim of this dissertation is to describe effects of TGF-β1 on cultured porcine vas deferens 
epithelial cells. Electrophysiological parameters, including transepithelial electrical resistance 
(Rte) and short circuit current (Isc), were measured to determine whether TGF-β1 would affect the 
barrier integrity of and/or ion transport across vas deferens epithelium. TGF-β1-induced 
electrophysiological changes in vas deferens potentially indicate whether TGF-β1 could affect 
male fertility and whether TGF-β1 would likely aggravate cystic fibrosis-related pathology. 
This chapter will start with an introduction of TGF-β1: production and activation; signaling 
pathways; and its physiological and pathological roles. The impact of TGF-β1 on fibrotic 
diseases, especially on cystic fibrosis, will be described specifically. The following component 
of this chapter will present the causes and the effects of cystic fibrosis, including the effect of 
cystic fibrosis on male fertility. The subsequent component will introduce the male reproductive 
tract, especially the vas deferens. Porcine vas deferens epithelial cells, including both cultures of 
freshly-isolated vas deferens epithelial cells and PVD9902 cells, will be presented. The tight 
junction integrity of the vas deferens epithelia, as well as the ion transport across this epithelium 
will also be discussed. 
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 Transforming Growth Factor Beta 1 
Introduction 
The TGF-β superfamily consists of structurally related cytokines that are involved in a wide 
range of cellular processes such as cell growth, cell migration, differentiation, proliferation, 
apoptosis, wound healing, and immune function. The large, and still growing, TGF-β 
superfamily consists of bone morphogenetic proteins, growth and differentiation factors, anti-
Muellerian hormone, activin, inhibin, nodal, and the TGF-β subfamily (53).  
Five members of the TGF-β subfamily have been identified: TGF-β1, TGF-β2 and TGF-β3 in 
mammals, TGF-β4 in birds, and TGF-β5 in amphibians. Among these isoforms, TGF-β1 is the 
most abundant. TGF-β1 was first reported in 1978 (24) following its discovery in the medium of 
murine sarcoma virus-transformed mouse fibroblast cells. The fibroblast-conditioned medium 
was concentrated by lyophilization and the dissolved concentrate induced colony formation of 
normal rat kidney fibroblasts in soft agar (24). Isolation of these factors using gel filtration 
chromatography identified two polypeptides that are responsible for the “transforming” activity, 
separately named TGF-α and TGF-β (2, 24). Later, TGF-α was characterized as a member of the 
epidermal growth factor family while TGF-β, the factor that had the property of inducing kidney 
fibroblast colony formation in soft agar, was identified as a growth factor that is not exclusively 
derived from tumors, but expressed at variable levels in numerous normal tissues, such as liver, 
heart, and kidney (80, 81).  
TGF-β1 Production  
TGF-β1 is translated as a precursor protein called pre-pro-TGF-β1 (Figure 1.1). Pre-pro-TGF-β1, 
in most mammals such as humans, mice, rats, pigs, and dogs, is a monomer that contains 390 
amino acids with an N-terminal pre-region (signal peptide; amino acids 1-29), a pro-region 
(latency associated peptide, LAP; amino acids 30-278), and the “mature” peptide (mature-TGF-
β1; amino acids 279-390) at the C-terminus. The signal peptide directs the translocation of pre-
pro-TGF-β1 and is cleaved off in the endoplasmic reticulum. After cleavage of the signal 
peptide, two monomers are linked by disulfide bonds in both the LAP and the “mature” peptide 
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portions of pre-pro-TGF-β1 to form a homodimer called pro-TGF-β1. The pro-TGF-β1 later is 
processed proteolytically in the Golgi by furin, a pro-protein convertase, yielding a dimer of LAP 
and a dimer of mature-TGF-β1. Although the peptides are cleaved by furin, the LAP dimer and 
the mature-TGF-β1 dimer remain associated non-covalently to form a latent complex called the 
small latent complex (SLC) with a molecular mass of ~100 kDa. Within the Golgi, the LAP 
dimer of SLC covalently binds to the latent TGF-β-binding protein (LTBP) and forms the large 
latent complex (LLC) with a molecular mass of ~220 kDa (62). LTBP belongs to the superfamily 
of fibrillin-like extracellular matrix (ECM) proteins, interacts with other ECM proteins such as 
fibrillin and fibronectin, and thus targets LLC to the ECM for the storage of TGF-β1 (68). 
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Figure 1.1 Schematic representation of the structure of TGF-β1 and the formation of latent 
TGF-β1 complexes. 
TGF-β1 is synthesized as pre-pro-TGF-β1 and undergoes several processing steps prior to its 
secretion, as indicated: 1) the signal peptide is cleaved off; 2) two monomers dimerize through 
disulfide bonds to form pro-TGF-β1; 3) pro-TGF-β1 is cleaved by furin and forms small latent 
complex (SLC), a non-covalent association of “mature” TGF-β1 dimer and latency associated 
peptide (LAP) dimer; 4) SLC binds to the latent TGF-β-binding protein (LTBP) and forms large 
latent complex (LLC). 
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Activation of TGF-β1 
Activation of latent TGF-β1 releases biologically active TGF-β1, which binds to TGF-β1 
receptors and elicits multifunctional activities. The activation process involves 2 steps: first, 
LTBP is cleaved, releasing the LLC from the ECM; second, the LAP dimer goes through a 
conformational change or proteolysis, disrupting the non-covalent interaction between the LAP 
dimer and the “mature” TGF-β1 dimer. The disruption of the non-covalent association releases a 
25 kDa dimer of “mature” TGF-β1, which is the active form of TGF-β1. 
Latent TGF-β1 can be activated by the cellular microenvironment, including pH, temperature, or 
chaotropic agents. Acidification, alkalinisation, heating, and treatment with chaotropic agents, 
such as urea, denature LAP and release active TGF-β1. Lawrence et al (46) showed that 
activation of latent TGF-β1 in chicken embryo fibroblast cell-conditioned medium can be 
achieved by exposure to urea. Brown et al (10) reported that human recombinant latent TGF-β1 
can be activated by acidification using a pH between 4.1 and 3.1, by alkalinisation using a pH 
between 11.0 and 11.9, and by heating to >65°C. Lyons et al (51) demonstrated that extreme 
acid or base treatment at pH 1.5 or 12 can activate latent TGF-β1, while mild acid treatment at 
pH 4.5 can also activate latent TGF-β1, although its activating effect is much weaker than the 
treatment at pH 1.5.  
Latent TGF-β1 can be activated also by plasmin, a serine protease involved in the degradation of 
the ECM. Plasmin is released as an inactive enzyme precursor, plasminogen, from the liver into 
circulation. Plasminogen can be converted into active plasmin by tissue plasminogen activator, 
kallikrein and factor XII (Hageman factor). Plasmin promotes the proteolytic cleavage of LTBP 
from ECM as well as the degradation of LAP and, thus, the release of active TGF-β1. Treatment 
of rat kidney fibroblastic cell-conditioned medium with plasmin resulted in the activation of 
latent TGF-β1 to an extent similar to that of mild acid (pH 4.5) (51). Plasmin inhibitors, such as 
aprotinin, ε-amino-n-caproic acid, and α2 plasmin inhibitor, blocked the inhibitory effect of 
active TGF-β1 on cell movement (83). These outcomes identify the critical role of plasmin in the 
activation of latent TGF-β1. 
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The activation of latent TGF-β1 is also mediated by thrombospondin-1 (TSP-1), a matricellular 
glycoprotein. TSP-1 interacts with both LAP and the “mature” TGF-β1 to form a trimolecular 
complex, which leads to a conformational change of LAP followed by a release of active TGF-
β1 (18). Similar to TGF-β1 null mice, TSP-1 null mice showed vascular muscle hyperplasia, 
alveolar hemorrhage, bronchial epithelial hyperplasia, and pancreatic islet cell hyperplasia. 
These pathological abnormalities in TSP-1 null mice were normalized with TSP-1-derived 
peptide (18). Additionally, treatment with blocking peptide that interferes with the activation 
process of TGF-β1 by TSP-1 reduced the abundance of active TGF-β1 and decreased glomerular 
ECM accumulation and decreased proteinuria in a mouse model of proliferative 
glomerulonephritis (21). All these outcomes suggest that TSP-1 regulates the activation of TGF-
β1. 
Integrins, transmembrane receptors that mediate the attachment between cells and ECM, are 
TGF-β1 activators as well. αvβ6 was the first integrin identified as a TGF-β1 activator (57). αvβ6 
binds to LAP, pulls LAP from the “mature” TGF-β1, and releases active TGF-β1 by cell 
movement (41). αvβ6-expressing cells induced increased TGF-β1 activity, and the increased 
TGF-β1 activity can be blocked by antibodies raised against either active TGF-β1 or αvβ6 (57). 
Similar to TGF-β1-null mice, αvβ6-null mice (33) and mice with a mutation of the integrin-
binding site (106) developed inflammation of many organs, suggesting that integrin αvβ6 
activates latent TGF-β1.  
Expression of TGF-β1  
TGF-β1 is ubiquitously expressed. Immunohistochemical labeling demonstrated high abundance 
of TGF-β1 in adrenal gland, bone marrow, kidney, ovary, and placenta as well as the widespread 
expression of TGF-β1 in other tissues such as cartilage, heart, pancreas, skin, and uterus in adult 
mice (95). Outcomes from northern blots showed that TGF-β1 mRNA is expressed in every 
tissue examined (95).  
TGF-β1 is also present at measurable levels in body fluids and secretions, suggesting that it may 
have an endocrine or lumicrine function (Table 1.1). A fact worthy of attention is the relatively 
high abundance of TGF-β1 in seminal plasma, which is more than 17 fold of its concentration in 
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normal human plasma (60, 70). The concentrations of many cytokines in seminal plasma of 
fertile men, including interleukin-1, -2, -5, -6, -7, -10, -12, -13, and -17, tumor necrosis factor-α, 
interferon-α, interferon-γ, TGF-β1, granulocyte colony-stimulating factor, and granulocyte-
macrophage colony-stimulating factor, have been quantitated. Among these cytokines, TGF-β1 
is present in the highest concentration and it is present in all samples (70). The high 
concentration of TGF-β1 in seminal plasma suggests that it likely plays an important role in 
reproductive success and that there maybe effects in the male reproductive tract. We speculate 
that dysregulation of TGF-β1 activity in the male reproductive tract could have clinical 
importance. The effects of TGF-β1 on vas deferens epithelial cells are reported in Chapter 2 and 
Chapter 3. 
Table 1.1 TGF-β1 concentrations reported in normal human fluids 
Human fluid TGF-β1 concentration 
Plasma 5 ng/ml 
Urine 300 pg/mg creatinine 
Synovial effusion < 1 ng/ml 
Cerebrospinal fluid 20.5 pg/ml 
Bronchoalveolar lavage fluid 5.5 pg/ml 
Seminal plasma 85-238 ng/ml 
Table modified from (60, 62, 70). 
TGF-β1 Signaling 
TGF-β1 regulates multiple cellular processes through a general mechanism in which active TGF-
β1 binds to and activates transmembrane receptors, initiates the canonical Smad signaling 
pathway and/or non-canonical signaling pathways, and thus mediates biological effects (14, 
108). 
TGF-β Receptor Activation 
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TGF-β receptors, including receptor I and receptor II, are required for TGF-β signal transduction 
(Figure 1.2). Both TGF-β receptor I and TGF-β receptor II contain a small cysteine-rich 
extracellular region, a single transmembrane region, and an intracellular region that contains a 
serine/threonine protein kinase domain. TGF-β receptor I also contains an intracellular region, 
named the GS domain, that is rich in glycines and serines (53).  
In the absence of TGF-β1, both receptor I and receptor II exist as homodimers in the cell surface. 
TGF-β1 binds to the pre-formed dimer of TGF-β receptor II to initiate TGF-β1 signaling. The 
binding of TGF-β1 to TGF-β receptor II dimer allows subsequent recruitment of TGF-β receptor 
I dimer and results in the formation of a stable tetrameric receptor complex. TGF-β receptor II is 
a constitutively active kinase. Upon formation of the ligand-induced receptor complex, TGF-β 
receptor II transactivates receptor I by phosphorylation at serine and threonine residues in their 
GS domains. Activated TGF-β receptor I activates the canonical signaling pathway and/or non-
canonical signaling pathways (89).  
The Canonical Smad Signaling Pathway 
Smad proteins were the first identified effectors for TGF-β receptors (54). They are the 
vertebrate homologues of the Drosophila protein MAD (mothers against decapentaplegic) and 
the Caenorhabditis elegans protein SMA (small body size). Smad proteins are divided into 3 
groups based on their functions: the receptor-activated Smads (R-Smads, Smad1, 2, 3, 5, and 8), 
the common mediator Smad (Co-Smad, Smad4), and the inhibitory Smads (I-Smads, Smad6 and 
7). Smad2 and Smad3 mediate signals from TGF-β1 and affect the transcription of target genes, 
while Smad7 regulates TGF-β1 responses by a negative feedback mechanism (Figure 1.2). 
After TGF-β1 binding and the consequent phosphorylation of TGF-β receptor I, Smad2/3 are 
recruited to the receptor complex with the assistance of Smad anchor for receptor activation 
(SARA), a protein that interacts with both the receptor complex and Smad2/3. Upon the binding 
to the TGF-β1 receptor complex, Smad2/3 are phosphorylated directly by TGF-β receptor I. The 
phosphorylation-activated Smad2/3 dissociate from both the receptor complex and SARA. With 
the aid of scaffolding proteins such as TGF-β receptor I associated protein-1 (TRAP-1), Smad4 
is bound to phosphorylated Smad2/3 to form an R-Smad/Co-Smad complex. The R-Smad/Co-
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Smad complex translocates into the nucleus, recognizes and binds to Smad binding elements 
(SBE) in the promoter sequences of target genes, interacts with additional transcription co-
regulators, regulates the expression of target genes, and thus affects various cell functions. The 
transcription co-regulators include factors such as activator protein-1 (AP-1) and forkhead box 
protein H1 (FOXH1 or FAST-1) and co-activators such as CBP/p300.  
The Smad signaling pathway is negatively controlled by I-Smads. Smad7 competes with 
Smad2/3 for the binding site on the activated TGF-β receptor complex, prevents Smad2/3 from 
being phosphorylated, and blocks downstream activation of the Smad signaling pathway (14, 
53). 
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Figure 1.2 Schematic representation of the canonical Smad signaling pathway. 
Upon the binding of TGF-β1 to TGF-β receptor II and the subsequent formation of the activated 
TGF-β receptor II and receptor I complex, Smad2/3 are recruited and phosphorylated. 
Phosphorylated Smad2/3 initiate the canonical Smad signaling pathway. Phospho-Smad2/3 are 
then released from the TGF-β receptor complex and form a complex with Smad4. The formed 
Smad complex relocates to the nucleus, interacts with Smad binding elements (SBE), and 
regulates cell-specific target gene(s). The canonical Smad pathway is inhibited by Smad7. 
SARA, Smad anchor for receptor activation; TRAP-1, TGF-β receptor I associated protein-1. 
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In addition to directly regulating gene expression in the canonical signaling pathway, Smad 
proteins also regulate other pathways, e.g. the protein kinase A (PKA) signaling pathway (104, 
105, 107). PKA is activated typically by the elevation of intracellular cAMP concentration. 
Independently of cAMP, TGF-β1-induced Smad3/Smad4 complex binds to the regulatory 
subunits of PKA, releases the PKA catalytic subunits, and activates the PKA signaling pathway. 
This mechanism reportedly contributes to the growth inhibition and epithelial-mesenchymal 
transition (EMT) (105, 107).  
The Non-Canonical Signaling Pathways 
Emerging evidence suggests that the Smad signaling pathway does not explain all TGF-β1-
associated effects. In addition to the canonical Smad signaling pathway (Figure 1.2), TGF-β1 
also is able to induce signals through the activation of non-canonical signaling pathways, 
including the c-Jun N-terminal kinase (JNK), the p38 mitogen-activated protein kinase (p38 
MAPK), the extracellular signal-regulated kinase (Erk), the Ras homolog (Rho)-like GTPase, 
and the phosphoinositide 3-kinase (PI3K) signaling pathways. 
p38 MAPK- and JNK-activated cascades are the most-studied pathways among the non-
canonical signaling pathways (Figure 1.3). When TGF-β receptor I is in its non-phosphorylated 
basal state, it interacts with TGF-β-activated kinase 1 (TAK1), a serine/threonine kinase in the 
mitogen-activated protein kinase kinase kinase (MAPKKK) family, TAK1-binding protein-2 
(TAB2), and tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6), a ubiquitin 
ligase that catalyzes the ubiquitylation of itself and other molecules upon ligand binding (45). 
Upon the binding of TGF-β receptor II and the subsequent phosphorylation of TGF-β receptor I, 
TRAF6 undergoes auto-ubiquitination and induces the ubiquitination and dissociation of TAK1 
from the TGF-β receptor complex. Released TAK1 binds to TAK1-binding protein-1 (TAB1), 
which triggers the autophosphorylation and activation of TAK1. Activated TAK1 phosphorylates 
MAP kinase kinase 3/6 (MKK3/6) and/or MAP kinase kinase 4 (MKK4), which phosphorylate 
and activate p38 MAPK and JNK, respectively (45). Activated p38 MAPK and/or JNK target 
transcription factors, such as activating transcription factor 2 (ATF2) and c-Jun, activate or 
repress target genes, and regulate cellular responses such as apoptosis and EMT (16, 108). 
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Figure 1.3 Schematic representation of the JNK/p38 MAPK signaling pathway. 
Upon the activation of TGF-β receptor complex, auto-ubiquitination of tumor necrosis factor 
(TNF) receptor-associated factor 6 (TRAF6) induces the ubiquitination and release of TGF-β-
activated kinase 1 (TAK1). TAK1 interacts with TAK1-binding protein-1 (TAB1) and is then 
auto-phosphorylated. Phosphorylated TAK1 transmits TGF-β1 signals to the p38 MAPK and the 
JNK signaling pathway to regulate target genes. Ub, ubiquitin. 
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In addition to the p38 MAPK and the JNK pathway, TGF-β also activates the Erk signaling 
pathway. Activated TGF-β receptor complex recruits growth factor receptor binding protein 2 
(GRB2) and Son of Sevenless (SOS). SOS catalyzes the Ras exchange of GDP for GTP and thus 
activates Ras, Raf, and their downstream target Erk. Activated Erk affects transcription factors 
such as Snail, a repressor of E-cadherin transcription, and thus mediates EMT (108).  
Members of the Rho-like GTPase family also are involved in TGF-β1 signaling in polarized 
epithelial cells. Upon the binding of TGF-β1, Par6, a scaffold protein that colocalizes with TGF-
β receptor I at tight junctions, is phosphorylated by the receptor complex. Phosphorylated Par6 
recruits Smurf1 and mediates the ubiquitination and degradation of RhoA, which enables the 
dissolution of tight junctions during EMT (63).  
Another kinase that is activated by TGF-β1 is PI3K. Activated TGF-β receptor complex, 
possibly through a physical interaction, activates PI3K, and phosphorylates its downstream 
effector Akt. Activated Akt further phosphorylates glycogen synthase kinase 3β (GSK3β) and 
inhibits its activity (39). GSK3β inhibition is associated with elevated Snail transcription, and 
thus mediates EMT (4). 
In conclusion, the full spectrum of biological responses to TGF-β1 depends on multiple signaling 
pathways that involve the canonical Smad signaling pathway as well as various non-canonical 
signaling pathways.   
Physiological and Pathological roles of TGF-β1  
TGF-β1 plays critical roles in many physiological functions such as the immune response, cell 
proliferation, apoptosis, differentiation, production of ECM, and EMT (62). Malfunctions of the 
TGF-β1 signaling pathway are implicated in a variety of pathological processes including 
autoimmune diseases, cancer, and fibrotic disorders. 
TGF-β1 and Autoimmune Diseases 
TGF-β1 regulates the proliferation, differentiation, and survival of lymphocytes and thus controls 
the immune system. For T lymphocytes, TGF-β1 inhibits the proliferation of T cells, blocks the 
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differentiation of T helper cells and cytotoxic T lymphocytes, induces the generation of 
regulatory T cells, and promotes the survival of T cells during T cell expansion and 
differentiation (49). For B lymphocytes, TGF-β1 inhibits the proliferation and activation of B 
cells, induces apoptosis in immature B cells and resting B cells, and regulates the production of 
immunoglobulin (48, 49). Besides its diverse roles in lymphocytes, TGF-β1 inhibits the 
functions of other immune cells such as natural killer cells, dendritic cells, and macrophages 
(49). 
The protective role of TGF-β1 in many autoimmune diseases has been well documented. TGF-
β1 knockout mice developed hallmarks of autoimmune diseases such as a progressive 
lymphocyte infiltration into multiple organs that led to death at about 3 weeks after birth due to 
compromised organ function (48). Intraperitoneal injection of TGF-β1 to mice inhibited 
collagen-induced arthritis and experimental allergic encephalomyelitis (44). Similarly, the 
administration of antibody to TGF-β1 exacerbated the severity of experimental allergic 
encephalomyelitis (55, 75). Consistent with the immunosuppressing role of TGF-β1, decreased 
production of TGF-β1 was found in patients with autoimmune diseases such as systemic lupus 
erythematosus (61) and multiple sclerosis (56). On the other hand, in later stages of autoimmune 
diseases, the infiltration of inflammatory cells stimulates the local production of TGF-β1, which 
contributes to dysregulated tissue repair and remodeling, and eventually leads to tissue fibrosis 
and organ damage (84). In autoimmune-prone (NZB/W F1) mice, although the expression of 
TGF-β1 in the lymphoid tissue was reduced compared with its expression in non-autoimmune 
mice, elevated levels of TGF-β1 in the kidney correlated with chronic renal lesions (involving 
mesangial matrix deposition, glomerular scars, tubular atrophy and interstitial fibrosis), 
suggesting that TGF-β1 plays dual roles in the pathogenesis of organ damage in autoimmune 
diseases (84). 
TGF-β1 and Cancer 
TGF-β1 regulates the cell cycle and thus controls cellular proliferation. In epithelial cells, TGF-
β1 arrests the cell cycle at the G1 stage, inhibits cell proliferation, and promotes cell apoptosis. 
In cancer cells that have mutations in one or more components of the TGF-β1 signaling pathway, 
TGF-β1 fails to arrest cell growth or proliferation (8). TGF-β1 also can induce EMT, a biological 
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process characterized by reduced expression of cell junction proteins and the upregulation of 
mesenchymal proteins. During EMT, epithelial cancer cells lose their epithelial polarity, acquire 
more migratory mesenchymal cell-like properties, and gain enhanced mobility and invasiveness 
(38). 
The different effect of TGF-β1 on normal cells versus cancer cells contributes to the dual role of 
TGF-β1 in carcinogenesis. At early stages of tumor development, TGF-β1 acts as a growth 
inhibitor and tumor suppressor. Mice heterozygous for the deletion of the TGF-β1 gene, that 
express only 10-30% of wild-type TGF-β1 protein, exhibited enhanced tumorigenesis compared 
to their wild-type littermates in response to chemical carcinogens (93). The tumor-prone 
syndromes in transgenic mice suggest that TGF-β1 has a protective effect. At later stages of 
tumor development, tumor cells become resistant to the growth inhibition role of TGF-β1. TGF-
β1, via its effects on migration and invasion, acts as a tumor promoter. Elevated plasma levels of 
TGF-β1 have been identified in cancer patients, such as patients with hepatocellular carcinoma 
(36), breast cancer (37), and colorectal cancer (96). Additionally, a strong correlation between 
elevated serum levels of TGF-β1 and cancer invasion has been demonstrated (50, 103). Mice 
with TGF-β1 overexpressed in keratinocytes have been exposed to long-term carcinogens. These 
transgenic mice showed a suppressed benign tumor outgrowth 10-25 weeks post carcinogen 
initiation, but an enhanced malignant conversion rate after 26 weeks, suggesting the dual action 
of TGF-β1 in cancer (19).  
TGF-β1 and Fibrotic Diseases 
TGF-β1 stimulates ECM production, and thus accelerates wound healing and repair (9, 47). 
Excessive or sustained secretion of TGF-β1 induces a pathological excess of tissue repair and 
thus leads to fibrotic diseases of many organs (42, 102). Patients with fibrotic disease, including 
liver cirrhosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and skin 
fibrosis exhibit increased mRNA levels of TGF-β1 (6, 9, 23, 92).  
A strong correlation between cystic fibrosis and TGF-β1 also has been identified (9). An in vitro 
study showed that cystic fibrosis epithelial cells produce increased levels of TGF-β1 when 
compared with non-cystic fibrosis controls (66). Genetic polymorphisms in the TGF-β1 gene 
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associate with the severity of cystic fibrosis lung disease (17). Notably, genetic variations affect 
the production of TGF-β1. For the single nucleotide polymorphism at position +869 (C or T) in 
codon 10, the TGF-β1 polymorphism T/T is associated with high TGF-β1 production and 
thereby has been designated as the TGF-β1 ‘high producer’ genotype. It follows that other 
polymorphisms (T/C or C/C) in codon 10 are called TGF-β1 ‘low producer’ genotypes. Clinical 
information from 171 patients suggested that cystic fibrosis patients having the TGF-β1 high 
producer genotype experienced a more rapid deterioration in lung function and developed a more 
severe lung disease (3). Direct measurement of TGF-β1 also suggested that the concentration of 
TGF-β1 affects the severity of cystic fibrosis. TGF-β1 levels in bronchoalveolar lavage fluid of 
pediatric cystic fibrosis patients is higher than that of non-cystic fibrosis children undergoing 
bronchoscopy for the evaluation of chronic/recurrent wheeze or recurrent pneumonia. 
Additionally, in cystic fibrosis children, an increased TGF-β1 level is associated with reduced 
forced expiratory volume in one second (FEV1), suggesting a correlation between TGF-β1 levels 
and lung function (31). In pediatric cystic fibrosis patients, plasma TGF-β1 levels also correlate 
with the severity of lung disease. After antibiotic treatment for a pulmonary exacerbation, plasma 
TGF-β1 level decreased and FEV1 improved (30). Additionally, TGF-β1 exposure attenuates the 
efficacy of correctors of ΔF508, the most common CFTR mutation, indicating that TGF-β1 may 
interfere with the cystic fibrosis clinical therapy aimed to rescue the functional defect of ΔF508 
(88). All these observations suggest that higher TGF-β1 expression aggravates or increases the 
clinical severity of cystic fibrosis.  
 
 Cystic Fibrosis  
Cystic fibrosis is a life-shortening disease first described by Dr. Dorothy Andersen in 1938 (1). It 
is the most common life shortening autosomal recessive diseases in Caucasians. According to 
data from the Cystic Fibrosis Foundation, it affects ~30,000 children and adults in the United 
States and ~70,000 worldwide while more than 1000 new cases are diagnosed annually (58). 
Cystic fibrosis is caused by defects in the gene that encodes CFTR, an anion channel that 
contributes to fluid and electrolyte transport across epithelia. 
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CFTR Gene and Protein 
CFTR was localized to chromosome 7 in 1985 and was subsequently identified in 1989 (79, 
100). The gene spans ~250,000 base pairs and consists of 27 exons (Figure 1.4). These 27 exons 
were previously numbered 1-24 with subdivisions of exon 6 (6a and 6b), exon 14 (14a and 14b) 
and exon 17 (17a and 17b) (110).  
CFTR codes for a 1480 amino acid glycoprotein with a mature molecular mass of ~170,000 Da. 
Mature CFTR, in most cases, is located in the apical membrane of epithelial cells, where it 
provides a pathway for anion secretion. The protein contains five functional domains: two 
membrane-spanning domains (MSD1 and MSD2), each of which is composed of six 
transmembrane segments, two cytoplasmic nucleotide-binding domains (NBD1 and NBD2), and 
a regulatory domain (R; Figure 1.4). The transmembrane domains contribute to the formation of 
the CFTR pore, which allows for the movement of chloride and/or bicarbonate across the 
membrane down their respective electrochemical gradients (22). Gating of the CFTR pore is 
regulated by the R domain, which contains several consensus sites for phosphorylation. 
Phosphorylation of the R domain, together with the presence of ATP, drives the opening of 
CFTR channel (35). CFTR is phosphorylated and activated by PKA. Therefore, factors that 
increase the generation of cAMP, such as the binding of agonists to receptors signaling through 
cAMP/PKA pathways, the activation of the adenylyl cyclase, and the inhibition of 
phosphodiesterase, activate anion permeation through CFTR channels (85, 86). CFTR can also 
be activated by protein kinase C (PKC), although to a lesser extent (5, 91). 
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Figure 1.4 Schematic representation of the human CFTR gene and protein. 
The diagram shows (a) the structure of CFTR with 27 exons; (b) the predicted structure of the 
resulting CFTR protein with five functional domains: membrane-spanning domain (MSD1), 
nucleotide-binding domain (NBD1), regulatory domain (R), MSD2, and NBD2; (c) the 
topological model of CFTR protein in the apical cell surface.  
Figure modified from (109). 
Since 1983, it has been demonstrated that cystic fibrosis leads to chloride impermeability in 
sweat glands, which suggests that CFTR is a chloride channel (72). Evidence also suggests that 
CFTR transports bicarbonate (34, 71). Under normal conditions, the CFTR protein functions as 
an anion channel that mediates the secretion of chloride and bicarbonate, which drives the 
movement of fluid into the luminal compartment across epithelial cells. Mutated CFTR codes for 
defective amounts and/or function of CFTR proteins. Defective CFTR protein causes impaired 
electrolyte and fluid secretion and dehydration of luminal contents in affected organs such as 
pancreas and airways throughout the respiratory system. Meanwhile, defective bicarbonate 
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secretion leads to a less alkaline luminal fluid in hollow organs or glands. These changes in the 
luminal components could induce organ damage and cause cystic fibrosis pathology in many 
organs. 
CFTR Mutations 
More than 1900 different mutations in CFTR have been identified to date (CFTR mutation 
database; http://www.genet.sickkids.on.ca/cftr). A large portion of these mutations represent the 
change in a single nucleotide or insertions or deletions of a number of nucleotides. Although 
many mutations have been documented, most of them are quite rare. Fewer than 20 mutations 
occur at a frequency higher than 0.1% while only 5 mutations (ΔF508, G542X, G551D, 
W1282X, and N1303K) occur at a frequency higher than 1% in cystic fibrosis patients.  
Various mutations of the CFTR gene affect function in different ways. CFTR mutations have 
been categorized into five functional classes (Figure 1.5). Class 1 (‘no synthesis’) mutations 
cause a premature signal to terminate RNA translation (stop codon), resulting in little protein 
production and few or no functional CFTR channels. G542X and W1282X belong to this class. 
Class 2 (‘block in processing’) mutations disrupt CFTR protein folding and adversely affect 
protein maturation. CFTR proteins are synthesized, but are not trafficked to the apical surface to 
perform their ion transport function. N1303K, as well as ΔF508, the most common mutant form 
of CFTR, belong to this class. Class 3 (‘block in regulation’) mutations affect CFTR channel 
gating. Therefore, there is little or no ion movement through CFTR channels even though CFTR 
is synthesized and trafficked to the apical cell surface. G551D belongs to this class. Class 4 
(‘altered conductance’) mutations cause defective anion transport through CFTR channels. 
R117H, a mutant form commonly associated with male infertility, but with lesser effects on 
pulmonary and digestive function, is an example of a class 4 mutation. Class 5 (‘reduced 
synthesis’) mutations cause reduced production of functional CFTR and thus a smaller amount of 
synthesized CFTR may reach the apical cell surface. A455E is a mutant form that belongs to 
class 5. 
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Figure 1.5 Normal CFTR and five functional classes of CFTR mutations. 
CFTR codes for CFTR channels while CFTR mutations lead to abolished or impaired functional 
CFTR channels. For normal CFTR, CFTR protein is synthesized, trafficked to the apical cell 
surface, and functions as a nucleotide-gated anion channel upon its activation by cAMP 
dependent phosphorylation. For CFTR mutations, little (class 1 to 3) or less (class 4 and 5) 
functional CFTR is present in the apical cell surface. 
Figure adapted from (90). 
The severity of cystic fibrosis is associated with different types of CFTR mutations and the 
amount of functional CFTR (Table 1.2). Individuals inherit one copy of CFTR from each parent. 
Those with two ‘normal’ CFTR have 100% normal CFTR function. People with one ‘normal’ 
and one mutant CFTR have 50-100% of normal CFTR function depending on the severity of the 
mutation. They are cystic fibrosis carriers who do not have apparent cystic fibrosis 
symptomology. About 1 in 25 Caucasians are cystic fibrosis carriers. Individuals harboring two 
mutant CFTR alleles are cystic fibrosis patients and suffer from cystic fibrosis-associated 
pathologies. The more severe mutations are associated with less CFTR function, leading to more 
severe disease manifestations (109). Classes 1 to 3 CFTR mutations (Figure 1.5) are typically 
‘severe’ CFTR mutations that express little or no functional CFTR at the apical cell surface while 
classes 4 and 5 are ‘mild’ or atypical CFTR mutations that include some residual CFTR function. 
For patients with two ‘severe’ CFTR mutations, the absence of functional CFTR leads to classic 
cystic fibrosis phenotype including meconium ileus, failure to thrive, distal intestinal obstruction, 
pancreatic insufficiency, recurrent bronchial infections and progressive pulmonary disease, salty 
sweat, obstructive biliary disease, and congenital bilateral absence of the vas deferens (CBAVD). 
21 
 
For patients with one ‘severe’ CFTR mutation and one ‘mild’ CFTR mutation and for patients 
with two ‘mild’ CFTR mutations, the expressed CFTR protein retains some function and these 
patients exhibit less severe clinical manifestations. These patients generally will retain some 
pancreatic function and exhibit reduced pulmonary involvement, but will have CBAVD. 
Heterozygosity for R117H and ΔF508 or homozygosity for R117H leads to CBAVD, suggesting 
that the male reproductive tract is more sensitive to any alterations in CFTR expression or 
activity (111).  
Table 1.2 CFTR channel function and CFTR-associated cystic fibrosis phenotype. 
Percentage of normal CFTR function Manifestations of CFTR 
< 1% Pancreatic insufficiency 
Plus manifestations listed below 
< 4.5% Progressive pulmonary disease 
Plus manifestations listed below 
< 5% Clinically demonstrable sweat abnormality 
< 10% Congenital bilateral absence of the vas deferens 
(male infertility) 
10-30% Some abnormalities 
31-49% No known abnormality 
50-100% No known abnormality (carriers) 
The relationships between the amount of normal CFTR function and clinical cystic fibrosis 
manifestation are listed. 
Table modified from “Cystic Fibrosis Medicine” (http://www.cysticfibrosismedicine.com). 
Effects of Cystic Fibrosis 
Cystic fibrosis affects many organs including sweat glands, airway, pancreas, gastrointestinal 
tract, liver, gallbladder, and the reproductive system.  
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The sweat gland secretory coil secretes an isotonic fluid into the lumen and then salt is 
reabsorbed in the sweat duct before secretion, releasing hypotonic sweat (73). In cystic fibrosis 
patients, due to the lack of functional CFTR, the chloride conductance in the sweat gland is 
abolished. The conductance of epithelial sodium channel (ENaC) is also reduced in CF sweat 
duct (78). Impaired sodium and chloride reabsorption leads to a high salt concentration in the 
sweat of cystic fibrosis patients (74). Therefore, the sweat test, which measures the concentration 
of chloride in solution on the skin surface, has been used to screen for cystic fibrosis. People with 
a chloride level of greater than or equal to 60 mEq/L are likely to be diagnosed as cystic fibrosis 
patients. 
Abnormal CFTR protein causes defective anion conductance on the apical cell surface of airway 
epithelial cells and leads to airway surface liquid depletion, mucus dehydration or lack of 
hydration, and mucus plugging of the airways. The thick mucus impairs ciliary movement, 
decreases mucociliary clearance, and prevents foreign particles and bacteria from being cleared 
effectively (99). Trapped foreign particles and bacteria lead to the infection, typically dominated 
by Staphylococcus aureus and Pseudomonas aeruginosa (27). Persistent and recurrent infections 
incite neutrophilic inflammatory responses (82), progress to chronic sinusitis and chronic lung 
disease, and result in the decline of lung function (77).  
CFTR dysfunction in the pancreas leads to a reduced secretion of bicarbonate into the pancreatic 
juice resulting in a reduced fluid pH that is not optimal for digestive enzymes (40, 64). 
Additionally, CFTR dysfunction reduces ductal fluid secretion, causing the obstruction of 
pancreatic ducts by protein precipitation. Blockage of the pancreatic ducts prevents the 
movement of digestive enzymes into the duodenum and thus causes malabsorption of nutrients. 
The accumulated digestive enzymes are thought to cause destruction of the pancreas due to 
autodigestion and eventually lead to pancreatic fibrosis or scarring (43). Ultimately, >85% of 
cystic fibrosis patients are pancreatic insufficient and require enzyme supplementation. 
In the gastrointestinal tract of cystic fibrosis patients, defective CFTR reduces the secretion of 
chloride and bicarbonate. Decreased electrolytes and water content result in the production of 
thick mucus (28). Accumulated intestinal mucus may lead to mucus obstruction, resulting in 
meconium ileus, an intestinal blockage that occurs in ~10% of newborns with cystic fibrosis 
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(74). Later in life, distal intestinal obstruction syndrome and constipation are frequently seen in 
cystic fibrosis patients (97). 
Dysfunction of CFTR expressed in the epithelial cells lining the biliary tract reduces electrolyte 
and fluid secretion and results in increased bile viscosity. Viscous bile can obstruct bile ducts, 
which leads to liver damage such as focal biliary cirrhosis (32). The thick and dehydrated bile 
stored in the gallbladder contributes to the formation of gallstones. Altered bile composition, 
together with pancreatic dysfunction, also impairs fat absorption and leads to steatorrhea (101).      
In the reproductive system of male cystic fibrosis patients, dysfunction of CFTR changes the 
anatomical structures of the epididymis, vas deferens and seminal vesicles, impairs the 
production and maturation of sperm, and leads to male infertility (76).  
Effects of Cystic Fibrosis on Male Fertility 
Reproductive duct abnormalities in male cystic fibrosis patients were first described in 1968 
(25). Most male cystic fibrosis patients are infertile. Male with cystic fibrosis exhibit testes that 
are normal or diminished in size, epididymides that are markedly reduced in size or partially 
absent, scrotum that is enlarged, seminal vesicles that are atrophic and dysfunctional, and vasa 
deferentia that are absent (90). About 98% of male cystic fibrosis patients are affected by 
CBAVD, which blocks the movement of sperm from the caput epididymis to the ejaculatory 
ducts and results in azoospermia (20, 94). Besides the changes in the anatomical structures of the 
male reproductive system, the semen of male cystic fibrosis patients show abnormalities 
including azoospermia, reduced volume, and reduced pH (25). 
Genetic screening in men with CBAVD suggested that a large portion of these individuals have 
mutations in their CFTR genes, although many do not exhibit classical clinical symptoms of 
cystic fibrosis (52). Cystic fibrosis carriers also exhibit a higher frequency of infertility than 
individuals with two normal CFTR alleles. Infertile men with normal vas deferens but reduced 
sperm quality exhibit a frequency of CFTR mutation that is significantly higher than the 
frequency of CF carriers in a general population (98). 
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The high frequency of male infertility in cystic fibrosis patients either with ‘mild’ or ‘severe’ 
mutations and in cystic fibrosis carriers suggests the importance of functional CFTR in the male 
reproductive system, especially in the vas deferens.  
 
 Vas Deferens  
Vasa deferentia are critical structures in the male reproductive tract (Figure 1.6). Sperm are 
produced in seminiferous tubules in the testis, but when leaving testis are not capable of 
achieving fertilization. These sperm mature and acquire motility during their passage through the 
epididymis. During ejaculation, the smooth muscle in the vas deferens wall contracts and propels 
sperm to pass through the vas deferens to the ejaculatory ducts, and finally through the urethra to 
the outside of the body. Vasa deferentia store sperm cells and conduct sperm forward. Moreover, 
ion transport across the epithelial cells lining the vas deferens can rapidly alkalinize the luminal 
environment to which sperm are exposed, thereby contributing to sperm activation. 
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Figure 1.6 Anatomical diagram of the human male reproductive system. 
The human male reproductive system contains a number of organs including scrotum, testes, 
epididymides, vasa deferentia, seminal vesicles, prostate gland, ejaculatory ducts, urethra, and 
penis. 
Figure modified from http://www.patient.co.uk/diagram/Male-Reproductive-system.htm. 
Obstruction or absence of the vas deferens leads to male infertility. This is seen commonly in 
cystic fibrosis patients and there is a higher incidence in CFTR mutation carriers as discussed in 
the previous section. In the following section, the morphology and the function of the vas 
deferens, ion transport across the vas deferens epithelia, and description of a cultured vas 
deferens epithelial cell line, PVD9902, will be introduced. 
Anatomical Structure of the Vas Deferens 
The vas deferens, also called sperm duct or spermatic deferens, is a thick-walled tube that begins 
at the caudal end of the epididymis in the scrotum, extends into the pelvic cavity to the back of 
the prostate, and joins with the seminal vesicles. There are two identical vasa deferentia 
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emerging from the two epididymides. Each is ~30 cm in length in adult humans and connects the 
left and right epididymides to the ejaculatory ducts. 
The morphology of the vas deferens is identified by a narrow lumen in adults and surrounding 
thick muscular coat (Figure 1.7). The tissue lining the lumen is a layer of the mucous membrane. 
The mucous membrane is a pseudostratified columnar epithelium. Surrounding the mucous 
membrane are lamina propria and 3 layers of smooth muscle: an inner longitudinal layer, a 
middle circular layer, and an outer longitudinal layer that is attached to adventitia (59). As the 
vas deferens ascends towards the bladder, it is surrounded by arteries, veins, and nerves to form 
structure surrounded by connective tissue that is called the spermatic cord. At the fundus of the 
bladder, the vas deferens enlarges to form the ampulla, which connects to the ejaculatory duct. 
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Figure 1.7 Cross-section of the vas deferens. 
The vas deferens comprises 4 layers: the mucosa epithelium (e), the lamina propria (lp), the 
muscular coat, and adventitia (a). The muscular coat contains three layers of smooth muscle:  the 
inner longitudinal layer (i), the middle circular layer (m), and the outer longitudinal layer (o).  
Figure adapted from (59). 
Primary Porcine Vas Deferens Cells and PVD9902 Cells 
Porcine vas deferens epithelial cells have been isolated and cultured in our laboratory to study 
their basic biology and especially ion transport. Primary cultures of cell derived from vas 
deferens express biochemical markers of epithelial cells, ZO-1 and cytokeratin, display a high Rte 
of ~3,900 Ω cm2, and respond to numerous neuro-hormonal agents such as norepinephrine, 
vasopressin, ATP, adenosine, and histamine (87). Freshly isolated and cultured vas deferens 
epithelial cells provide a powerful tool to study the epithelial function and the ion transport 
mechanism in vas deferens epithelial cells. 
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Primary porcine vas deferens cells provide valuable data. However, one of the major concerns is 
reliable access to tissues and potential variability due to donors and isolation protocols. To better 
characterize vas deferens epithelial cells, an immortalized porcine vas deferens epithelial cell 
line, PVD9902, was established and characterized (13). 
PVD9902 cells were derived from the isolation and culture of primary porcine vas deferens 
epithelial cells. After the initial isolation, the epithelial cells were passed continuously for more 
than 200 subcultures and cells spontaneously immortalized to form an epithelial cell line 
designated PVD9902. After numerous passages, cells retain their ability to proliferate in culture 
and their ability to form tight monolayers. The male porcine origin of PVD9902 cells has been 
demonstrated by chromosome characterization and its epithelial characteristic has been 
demonstrated by immunocytochemistry. In Ussing chamber experiments, cultured PVD9902 
cells exhibit a high basal Rte (>6,000 Ω cm2) and a response to forskolin that requires chloride, 
bicarbonate, and sodium in the bathing medium. RT-PCR results demonstrate the presence of 
mRNA coding for numerous membrane transport proteins in the cultured PVD9902 cells, 
including CFTR, SLC26A3, SLC26A6, and SLC4A4 (13). All the observations suggest that 
PVD9902 cells recapitulate most characteristics of primary porcine vas deferens epithelial cell 
cultures. Therefore, besides freshly isolated vas deferens epithelial cells, this porcine vas 
deferens epithelial cell line, PVD9902, provides another readily available cell model that can be 
used to characterize male reproductive function. 
Vas Deferens Epithelial Tight Junctions 
In epithelial cells lining the vas deferens, tight junction proteins are located near the apical cell 
surface of adjacent epithelial cells to form a physical barrier that restricts the permeability to 
fluid and solutes. The high basal Rte in cultured porcine vas deferens epithelial cells suggests that 
vas deferens epithelial cells form a very tight monolayer that effectively separates the luminal 
from the abluminal compartments. Additionally, immunohistochemical results suggest the 
presence of tight junction proteins in vas deferens epithelia (13, 87).  
Tight junctions contain three major types of transmembrane proteins: occludin, claudins, and 
junctional adhesion molecules (JAMs) (15). To date, 24 isoforms of claudins and 4 isoforms of 
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JAMs have been identified. Occludin and claudins are tetraspan proteins while JAMs are single 
transmembrane domain proteins. The extracellular domains of these tight junction proteins 
constitute barrier in the paracellular space while their carboxyl-terminal domains interact with 
tight junction-associated proteins such as ZO-1, ZO-2, and ZO-3. These ZOs have several PDZ 
domains, which are protein-protein interaction domains responsible for intermolecular 
association. Through these PDZ domains ZOs directly bind to transmembrane proteins and link 
them to the actin cytoskeleton (26). Tight junction proteins act as a physiological barrier between 
separate body compartments. Tight junction proteins, such as claudin-4, also form ion selective 
pores in the tight junctions and regulate paracellular permeability. Therefore, tight junctions in 
vas deferens epithelia mediate fluid and solute movement across epithelial monolayers and 
contribute substantially to the stability of the luminal microenvironment. 
 
Figure 1.8 Schematic representation of tight junction proteins. 
Tight junction proteins occludin, claudin-X, and junctional adhesion molecule-X (JAM-X) link 
to accessory proteins ZO-X, and thus link to the actin cytoskeleton. Claudin-X indicates claudin 
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family members 1-24, JAM-X indicates JAM family members 1-4, and ZO-X indicates ZO 
family members 1-3. 
Ion Transport across Vas Deferens Epithelia 
Emerging evidence has suggested that the vas deferens is more than a storage and transit tube. 
The pseudostratified epithelial cells in the vas deferens also function in ion secretion or 
absorption. Functional and molecular studies performed in cultured lamb and porcine vas 
deferens epithelial cells suggested that cells lining the vas deferens express CFTR and ENaC as 
well as SLC4A4, a sodium-bicarbonate cotransporter (7, 12). Moreover, studies focusing on the 
effects of neurotransmitters and hormones on vas deferens epithelium suggested that ion 
transport across vas deferens epithelial cells is tightly regulated both acutely and over extended 
periods (11, 29, 67, 87). 
A basic cellular model of vas deferens epithelial cells is proposed as shown in Figure 1.9 (13, 
87). In the apical cell surface, there exist CFTR channels as well as chloride-bicarbonate 
exchangers SLC26A3 and SLC26A6 while the basolateral cell surface includes sodium-
potassium-ATPase, sodium-potassium-chloride (NKCC) cotransporter, potassium channels, and 
the sodium-bicarbonate cotransporter SLC4A4. The expression of ENaC channel can be induced 
or upregulated by exposure to dexamethasone in primary cultures of vas deferens (7, 12). 
However, PVD9902 cells do not express the β subunit of ENaC (13). Therefore, ENaC is not 
shown in the cellular model. The presence of ion pumps, exchangers, cotransporters, and 
channels in the model of vas deferens epithelial cells has been demonstrated by molecular assays 
such as RT-PCR and western blot. In electrophysiological experiments, forskolin-stimulated ion 
transport can be selectively reduced by CFTR inhibitors, DASU-02, glibenclamide and GlyH-
101, by sodium-potassium-ATPase inhibitor, ouabain, by NKCC cotransporter inhibitor, 
bumetanide, by potassium channel inhibitors, clotrimazole and BaCl2, and by the sodium-
bicarbonate cotransporter inhibitor, DNDS (87). The effects of these blockers on forskolin-
stimulated Isc suggested that these ion pumps, cotransporters, and channels have regulated 
activities in these cells. Besides forskolin, exposure to norepinephrine, vasopressin, ATP, 
adenosine, or histamine also induces a substantial increase in Isc, suggesting that these neuro-
hormonal agents stimulate vas deferens epithelial ion transport (87).  
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Ion transport across vas deferens epithelia through the CFTR channel is highlighted in Figure 
1.9. We propose that chloride enters the cell at the basolateral membrane via NKCC and that 
bicarbonate enters the cell at the basolateral membrane via SLC4A4. Chloride and bicarbonate 
exit the cell across the apical membrane through CFTR. Upon exposure to agents that increase 
the intracellular cAMP generation such as forskolin, an adenylyl cyclase activator, CFTR 
channels are activated. Activated CFTR mediates the secretion of chloride and bicarbonate, and 
accounts for the elevated Isc. 
 
Figure 1.9 A proposed model to account for anion secretion by vas deferens epithelial cells. 
The vas deferens epithelial cells contain numerous membrane transport proteins including 
SLC26A3, SLC26A6, and CFTR in the apical cell surface and sodium-potassium-ATPase, 
NKCC, potassium channels, and SLC4A4 in the basolateral cell surface (13, 87).  
Ion transport across vas deferens epithelia modulates the microenvironment to which sperm are 
exposed, and thus, is of great importance. The epididymis is reported to establish an acid luminal 
environment for the maturation and the storage of sperm (65). pH measurements in anesthetized 
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boars showed that systemic adrenergic stimulation can cause a rapid and profound increase in 
luminal pH (69). As the sperm transit through the vas deferens before and during ejaculation, the 
sperm are exposed to an alkaline luminal environment, which induces sperm motility and 
initiates a process that is required to achieve fertilizing capacity. Numerous ion channels and 
transporters in the vas deferens epithelia provide for regulated transport and account for changes 
in lumen volume and composition. The secretion of bicarbonate also contributes to the regulation 
of luminal pH (Figure 1.9). Therefore, the membrane transport proteins in the vas deferens 
epithelial cells and ion transport stimulated by neurotransmitters and hormones across vas 
deferens epithelial monolayers have important physiological and pathophysiological 
implications. 
 
 Goals of the Present Study 
With the progression in medical care and the expanding life expectancy of cystic fibrosis 
patients, infertility has become a more pressing problem. Interventions to treat or circumvent 
abnormalities in reproductive duct architecture or function are sought to increase the opportunity 
of male cystic fibrosis patients to foster children. 
TGF-β1, a multifunctional cytokine, has been associated with the severity of cystic fibrosis lung 
disease. The goal of the present study was to determine whether TGF-β1 also affects vas 
deferens, an organ that is commonly affected in male cystic fibrosis patients. Functional and 
molecular assays were conducted to determine whether TGF-β1 modulates electrophysiological 
parameters of primary cultures of vas deferens epithelial cells (in Chapter 2) and cultured 
PVD9902 cells (in Chapter 3). 
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This chapter includes my contributions to a portion of the electrophysiological and western blot 
experiments. 
With the observation that TGF-β1 disrupts epithelial integrity, it was hypothesized that TGF-β1 
might decrease the abundance of tight junction proteins. Therefore, western blot analysis was 
performed to detect whether TGF-β1 affects the expression of tight junction proteins. I 
contributed to the quantitative detection of occludin. The outcomes suggest that there is no 
detectable change in the abundance of occludin after TGF-β1 treatment (see Figure 2.4). 
The potential mechanism(s) by which TGF-β1 affects vas deferens epithelial cells was 
investigated using a pharmacological approach. I performed the Ussing chamber experiments to 
determine whether the p38 MAPK (defined in this reprint as MAPK11) inhibitor SKF86002 
would abrogate the effect of TGF-β1. The outcomes suggest that p38 MAPK inhibition does not 
prevent TGF-β1-induced decreases in Rte (see Figure 2.6). 
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Abstract 
Epithelial cells lining the male excurrent duct contribute to male fertility by employing a number 
of physiological mechanisms that generate a luminal microenvironment conducive to 
spermatozoa maturation and storage. Among these mechanisms, male duct epithelia establish 
intercellular tight junctions that constitute a barrier to paracellular diffusion of water, solutes, 
large molecules and cells. Mechanisms regulating the male duct epithelial barrier remain 
unidentified. Transforming growth factor beta (TGFB) is a regulatory cytokine present in high 
concentrations in human semen. This study examined whether TGFB has any effects on 
epithelial function exhibited by primary cultures of porcine vas deferens epithelia (1oPVD). 
TGFB1-exposure caused a 70-99% decrease in basal transepithelial electrical resistance (Rte, a 
sensitive indicator of barrier integrity), while a significant decrease in anion secretory response 
to forskolin was detected at the highest levels of TGFB1 exposure employed. SB431542, a 
selective TGFB receptor I (TGFBRI) inhibitor, prevented decreases in barrier function. Results 
also demonstrated that TGFB1-exposure modifies the distribution pattern of tight junction 
proteins occludin and claudin 7. TβRI TGFBR1 is localized at the apical border of the native 
porcine vas deferens epithelium. Pharmacological inhibition of mitogen-activated protein kinase 
11 (also known as p38-MAPK) did not alter the effect of TGFB1 on Rte significantly. These data 
suggest that epithelia lining the vas deferens is subject to disruptions in the physical barrier if 
active TGFB becomes bio-available in the luminal fluid, which might be expected to 
compromise fertility. 
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Introduction 
Epithelia lining the male excurrent duct (i.e., efferent ducts, epididymis and vas deferens) 
contribute to the generation of specific luminal fluid compositions that are required for sperm 
cell maturation and male fertility, as recently emphasized by studies demonstrating infertility or 
subfertility in men and animal models carrying certain genetic mutations [1-4]. In addition, 
transport mechanisms employed by these specialized epithelia to promote sperm cell maturation 
- regulation of luminal water content [5, 6], ion secretion and absorption [7], pH regulation [8, 9] 
and protein secretion [10] - would not be successful without an effective physical barrier that 
restricts permeability [11]. Epithelial cells lining the male excurrent duct establish tight 
junctions, which function as an anatomical physical barrier to the movement of water, solutes 
and cells such as defense cell types and spermatozoa [12, 13]. Moreover, the male excurrent duct 
epithelial barrier is thought to include an immune-protective component that prevents 
autoimmune responses to sperm cells as they transit, mature or remain stored in the lumen of the 
excurrent system [13-15]. 
Transforming growth factor beta (TGFB) can induce pathological signaling in 
differentiated epithelial cells and lead to fundamental changes in cellular phenotype via 
epithelial-to-mesenchymal transformation (EMT). This process is at the causal core of life-
threatening diseases such as kidney and lung fibrosis [16-18]. Furthermore, TGFB receptor 
(TGFBR1) is co-localized with epithelial tight junctions, where it is structurally linked to 
occludin, a tight junction integral protein [19-21]. Importantly, activation of TGFBRs and 
receptor complex formation lead to rapid tight junction dissociations via a transcription-
independent mechanism [19, 20]. 
The male reproductive tract synthesizes and secretes relatively high amounts of TGFB. 
While normal human plasma concentrations are reportedly 2-18 ng/ml [22, 23], TGFB 
concentrations in human semen have been reported at 85-238 ng/ml [24, 25]. TGFB exists as a 
latent or inactive form and as an active form. Active TGFB1 can reach 2 ng/ml in human semen 
[24]. TGFB in semen is thought to exert an immune-regulatory effect on the female reproductive 
tract that contributes to spermatozoa survival and fertilization [26]. Additional participation of 
this signaling pathway in male fertility has been described with the TGFB1-null male mice kept 
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alive via anti-inflammatory therapy [27]. These mice exhibit major hypothalamic-pituitary-
gonadal dysfunction and are infertile [27]. 
The origin of TGFB in semen has not been determined with certainty. Importantly, high 
levels of TGFB immunoreactivity is present in rat epididymal epithelia [28], and coding 
sequences for TGFB isoforms and receptors are expressed in this tissue [29]. However, it 
remains unknown whether TGFB can regulate physiological parameters of male excurrent duct 
epithelia, and mechanisms and/or mediators of this signaling have not been identified in the male 
excurrent system. This study tested whether primary cultures of porcine vas deferens epithelial 
cells (1ºPVDs) [30] respond to TGFB1 exposure with any significant changes in epithelial 
barrier function and/or ion transport. Results from initial experiments led us to conduct 
additional assays to test for the selectivity of the effect detected and to identify a disruptive effect 
of TGFB signaling on vas deferens tight junctions. 
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Materials and Methods 
Tissue Acquisition and Epithelial Cell Isolation. Porcine vas deferens were 
surgically excised immediately postmortem from sexually mature boars at a local swine 
production facility, placed in ice-cold Hank’s buffered salt solution (mM composition: 137 NaCl, 
5.4 KCl, 0.4 KH2PO4, 0.6 Na2HPO4, 5.5 glucose) and transported to the laboratory where 
isolation of epithelial cells was performed as described in detail previously [30]. Segments of 
porcine vas deferens and skeletal muscle were harvested onto cryogenic tubes and snap-frozen in 
liquid nitrogen within seconds of excision and also transported to the laboratory, where they 
were kept at -80C until further use. 
Cell Culture. Isolated vas deferens epithelial cells were seeded on 25 cm2 tissue culture 
flasks and grown in Dulbecco’s Modified Eagle’s Medium (Invitrogen, Carlsbad, CA) with 10% 
fetal bovine serum (Atlanta Biologicals, Atlanta, GA) and 1% penicillin and streptomycin 
(Invitrogen), where they became confluent in 2-5 days. Subsequently, cells were lifted with 
phosphate buffered saline (PBS) containing trypsin and ethylene-diaminetetraacetic acid 
(Invitrogen), suspended in medium, and seeded on 1.13 cm2 Snapwell permeable supports 
(Corning-Costar; Cambridge, MA) where they formed confluent monolayers. Paired monolayers 
from each boar were fed every other day for at least 10 days post-seeding, and then assigned to 
experimental groups in a given assay. Exposure to active TGFB1 (R&D Systems, Minneapolis, 
MN) was achieved by its inclusion in the basal compartment medium, while SB431542 (Sigma, 
Saint Louis, MO), and protein kinase inhibitor SKF86002 (Sigma) were included in both the 
basal and apical culture media. Monolayers exposed to both TGFB1 and SKF86002 were first 
exposed to SKF86002 for 30-60 minutes prior to receiving media that contained TGFB1 in 
addition to the inhibitor. NMuMG and Cos-7 cells were also seeded on permeable supports and 
cultured with the same medium formulation and feeding protocol described above. NMuMG 
cells were cultured as epithelial cell monolayers for 10 days before lysis and protein isolation, 
while Cos-7 cells were cultured until confluence (2-3 days) and then fixed. 
Electrophysiology. Epithelial cell monolayers were mounted in modified Ussing flux 
chambers (model  DCV9, Navicyte; San Diego, CA; model P2300, Physiologic Instruments, San 
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Diego, CA), bathed symmetrically in Ringer solution (composition in mM: 120 NaCl, 25 
NaHCO3, 3.3 KH2PO4, 0.83 K2HPO4, 1.2 CaCl2, 1.2 MgCl2), maintained at 39oC and bubbled 
with 5% CO2-95% O2 to provide mixing and pH stability. Monolayers were clamped to 0 mV 
and short circuit current (Isc) was measured continuously with a voltage-clamp apparatus (model 
558C; University of Iowa, Dept. of Bioengineering, Iowa City, IA). Data were acquired digitally 
at 0.1 to 1 Hz with an Intel-based computer using a MP100A-CE interface and AcqKnowledge 
software (ver. 3.7.3; BIOPAC Systems, Santa Barbara, CA). Once recordings began, this system 
applied a 5-seconds bipolar voltage pulse every 100 seconds, and the resulting change in Isc was 
used to calculate transepithelial electrical resistance (Rte) via Ohm’s law. After at least 10 
minutes of recording in basal conditions, monolayers were exposed to forskolin (EMD 
Chemicals, Gibbstown, NJ). The assay was terminated once Isc-tracings became stable. 
Immunohistochemistry and Confocal Microscopy. Monolayers were fixed in 4% 
paraformaldahyde for 1 hour, washed in PBS five times, incubated twice in 0.2% Triton X-100 
(Sigma) for 5 minutes, and blocked in 5% bovine serum albumin (BSA, Thermo Scientific, 
Rockfort, IL) and 0.2% Triton X-100 for 1 hour. Native tissues were snap-frozen in liquid 
nitrogen minutes after dissection, blocked in freezing medium and sectioned (CM3050S 
Cryostat, Leica Microsystems Inc., Buffalo Grove, IL). Sections were collected onto slides, fixed 
in 4% paraformaldahyde for 15 minutes, washed in PBS and subject to the same subsequent 
procedure described above for monolayers, except blocking with BSA was conducted overnight. 
Primary antibody incubations were conducted overnight at 4oC with the following specifications: 
anti-occludin (Invitrogen catalog 331500, 3 µg/ml), anti-claudin 7 (Invitrogen catalog 349100, 3 
µg/ml), anti-TGFBR1 (Santa Cruz Biotechnology catalog sc-398G, 10 µg/ml) and anti-
phosphorylated MAPK11 (Cell Signaling Technology catalog 9215, 0.3 µg/ml). Secondary 
immunofluorescent labeling was conducted with Alexa 488 and/or 594 (Invitrogen, 2 µg/ml) for 
1 hour. Finally, monolayers or tissue sections received a fluorescent nucleic acid stain (DAPI, 
Invitrogen) and final washes prior to mounting on slides. Monolayers were positioned so that the 
permeable plastic support faced the slide and the apical cellular membranes faced the cover slip. 
Scanning confocal microscopy was performed (LSM 510 META and LSM 700, Carl Zeiss 
Microimaging Inc, Thornwood, NY). Fluorescent signals were acquired independently by 
different lasers and incorporated in each image. From monolayers, at least ten different unique 
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images were acquired and at least one stack of images was derived along the Z-axis (apical-to-
basolateral). Analysis of confocal microscopy images and Z-Stack projections were conducted 
with Zeiss LSM Image Browser (version 4.2.0.121, Carl Zeiss), then exported and compiled with 
Corel Draw X3 (version 13.0.0.739, Corel Corporation, Ottawa, Ontario, Canada). Individual 
fluorescent signal intensity was measured using ZEN 2010 (version 6.0, Carl Zeiss).  
Western Blot Analyses. Protein lysates were derived from 1oPVDs, NMuMG epithelial 
cell monolayers, native porcine vas deferens and skeletal muscle tissues via direct 
homogenization and lysis in a Laemmli sample buffer containing 2% SDS, Tris-HCl (62.5 mM) 
and proteinase inhibitors. Segments of native porcine vas deferens, which had been stored at -
80oC, were thawed and their lumens were flushed with PBS prior to homogenization. Following 
homogenization, samples were aspirated repeatedly through 25 or 30 gauge needles and 
centrifuged at 14000 rpm, for 15 min at 4oC. Protein concentration was determined by the micro 
BCA colorimetric assay (Pierce, Rockford IL) and/or a spectrophotometer (ND 8000, NanoDrop 
Products, Wilmington, DE). Prior to electrophoresis, β-mercaptoethanol, glycerin and 
bromophenol-blue were added and samples incubated at 95oC for 5 minutes. Equal protein 
masses from each sample were resolved on 4-18% Tris-HEPES-SDS gradient gels (Pierce). 
Blotting onto PVDF membranes (Millipore, Billerica, MA) was conducted at 40V, for 2 hours at 
4oC. Membranes were blocked in 5% molecular grade dry milk overnight at 4oC, and 
subsequently incubated overnight at 4oC with primary antibodies: anti-occludin (Invitrogen 
catalog 331500, 1 µg/ml), anti-claudin 7 (Invitrogen catalog 349100, 1 µg/ml), anti-TGFBR1 
(TβRI) (Santa Cruz Biotechnology catalog sc-398G, 10 µg/ml), and anti-actin (Sigma catalog 
A2066, 1:1000 dilution). Incubations in peroxidase-conjugated secondary antibodies (Pierce) 
were conducted for 1 hr at 20 ng/ml. Chemiluminescent signals were obtained with a suitable 
substrate (Pierce) and acquired digitally (Imagestation 4000R, Eastman Kodak Co., Rochester, 
NY or FluorChem HD2 imager, Alpha Innotech, San Leandro, CA). Measurements of band 
signal intensity was conducted with UN-SCAN IT Gel (version 6.1, Silk Scientific Inc., Orem, 
UT) and AlphaEase FC (version 6.0.0, Alpha Innotech). 
Statistical Analysis. Paired t-tests and analysis of variance were performed as 
appropriate. These tests, calculation of means and standard error of the mean were performed 
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with Excel Microsoft Office, Office Suite 2007 (Microsoft Corporation, Redmond, WA). Graphs 
were made with SigmaPlot version 10.0 (Systat Software Inc., Point Richmond, CA).  
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Results 
TGFB1 disrupts transepithelial resistance and epithelial transport across porcine vas 
deferens epithelia 
To test whether TGFB can induce changes in epithelial function in 1oPVDs, initial 
experiments employed paired monolayers that were either kept untreated or exposed to TGFB1 
(100 ng/ml) for 24 and 72 hours in conditions that have been reported previously [30]. Typical 
outcomes acquired with three monolayers of cells derived from a single vas deferens are depicted 
in Fig. 1A. The magnitude of periodic bipolar pulses is inversely proportional to the monolayer’s 
Rte. TGFB1-treated monolayers exhibited substantially reduced Rte; Rte was least in monolayers 
subject to the longest exposure. Overall, TGFB1 exposure for 24 hours caused a 90% decrease in 
Rte, while 99% of basal Rte was ablated in 1ºPVD monolayers exposed to TGFB1 for 72 hours 
(Fig. 1B). Longer-term exposure impaired forskolin-induced anion secretion across 1ºPVDs 
significantly (Fig. 1 A and C). Therefore, these initial outcomes suggested that TGFB1 induces a 
severe and time-dependent loss of barrier function in vas deferens epithelial cells, and that 
epithelial anion secretion can also be affected. 
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Figure 2.1 Transforming growth factor beta 1 (TGFB1, 100 ng/ml) causes time-dependent 
Rte decreases across primary cultures of porcine vas deferens epithelial cells (1ºPVD).  
A) Vertical deflections in these Ussing chamber recordings correspond to pre-set electrical 
pulses (5 mV) and their magnitude is inversely proportional to Rte. Note that very small pulses 
are present throughout the untreated recording. Pulses shown defined that RTE at basal state was 
4800, 400 and 50 Ohms*cm2 in untreated, 24 and 72 hours, respectively. B) Basal Rte was 
significantly reduced after 24 and 72 hours exposure to TGFB1 (100 ng/ml). C) The ability to 
respond to intracellular cAMP-generation (forskolin) with increases in short circuit current (Isc), 
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indicating net anion secretion or cation absorption) was significantly reduced after 72 hours 
exposure to TGFB1. * indicates statistically different from untreated (n = 6, P<0.05). 
A subsequent set of assays was conducted to test for reproducibility of the TGFB1-effect 
on Rte when exposure is limited to 5 ng/ml for 24 hours. Concurrently, we sought to determine 
whether this effect was linked to selective TGFBR activation. Consistent with the initial 
observations, TGFB1-treated 1ºPVDs exhibited a large decrease (95%) in Rte (Fig. 2A-B). 
SB43152, a selective TGFBR1 inhibitor, abrogated the TGFB1 effect on Rte. In fact, 1ºPVDs 
exposed to both TGFB1 and TGFBR1-inhibitor had slightly greater Rte on average than untreated 
1ºPVDs, although no statistically significant difference was detected between these two groups. 
Mean forskolin-induced Isc changes were reduced by TGFB exposure although statistically 
significant differences were not observed (Fig. 2A and 2C). Collectively, results from these 
experiments provide compelling evidence that selective activation of TGFBRs in vas deferens 
epithelial cells leads to severe losses of barrier function, although the underlying mechanism is 
not fully defined. 
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Figure 2.2 A selective TGFB receptor I inhibitor (TGFBR1) R1Inh abolishes the TGFB1 (5 
ng/ml, 24 hours) effect on Rte across 1ºPVDs.  
A) Isc tracings depict the impact of 5 mV pulses on the 3 experimental groups and reveal that Rte 
in 1ºPVD exposed to TGFB1 plus RIInh SB431542 (10 µM) was similar to that in untreated 
1ºPVD. B) Summary of observations reveal that monolayers exposed to TGFB1 only had a 
significant RTE decrease, and monolayers exposed to TGFB1 plus RIInh exhibited mean basal Rte 
that was greater than untreated, although not significantly different. C) Forskolin-induced anion 
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secretion is not significantly altered across experimental groups. * indicates statistically different 
from the other 2 groups (n = 5, P<0.05). 
 
TGFB1 induces disruptions in tight junction protein immunoreactivity in porcine vas 
deferens epithelial cells 
TGFBR1 localization has been shown to be restricted to tight junctions where it has 
direct protein-protein interactions with occludin, and binding of TGFB to TGFBRs reportedly 
leads to the formation of a phosphorylated receptor complex that induces tight junction 
dissociations [19-21]. Thus, we hypothesized that changes in occludin immunoreactivity might 
be associated with TGFB1-induced decreases of Rte in 1ºPVDs, and tested this via scanning 
confocal microscopy. Severe disruptions of occludin-immunoreactivity were detected in 1ºPVDs 
exposed to 100 ng/ml for 72 hours in that the typical reticular pattern was unrecognizable and 
largely absent (Fig 3A). Only incomplete and irregular occludin strands were detected. At first 
examination, monolayers exposed to 5 ng/ml for 24 hours appeared to preserve the reticular 
pattern but abnormalities were clearly present under close examination. Punctate occludin 
immunoreactivity that was localized away from tight junction strands and largely distributed 
below the apical region (as seen in Z-stack projection, Fig. 3A) was consistently detected in this 
experimental group. In addition, a number of occludin strands were apparently dissociated in a 
manner that seemed to have generated hemi-strands that pulled apart and remained with each of 
the neighboring cells (Figs 3A and 3B). Based on these results, it was hypothesized that other 
integral tight junction proteins are similarly affected by TGFB1 exposure. Among the claudins 
expressed in more distal portions of the male excurrent duct, claudin 7 is one of the most 
abundant [12]. Therefore, the immunoreactivity pattern of claudin 7 was also tested. Outcomes 
from these experiments suggest that severe disruptions in the reticular pattern of claudin 7 occur 
after exposure to TGFB1 exposure (Fig. 3C). 
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Figure 2.3 TGFB1 exposure induces disruptions in tight junction protein organization in 
vas deferens epithelia.  
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A) Untreated 1ºPVD monolayers exhibit a uniform reticular occludin immunoreactivity pattern 
(red) that is localized apically, above nuclei (blue), as seen in orthogonal projections displayed as 
banners located at the top and right of each of the left-column images. Severe disruption of the 
reticular occludin immunoreactivity pattern is present in monolayers exposed to TGFB for 72 
hours (100 ng/ml), while exposure for 24 hours (5 ng/ml) induced abnormalities such as 
punctuate distribution and strand irregularity. Arrow heads indicate locations where occludin 
strands were apparently dissociated onto two hemi-strands. Single images (second column in 
panel A) are derived from a plane where occludin immunoreactivity was most abundant. B) 
Additional single Z-slice images derived from 1ºPVD exposed to 5 ng/ml for 24 hours show 
length-wise tight junction dissociations (arrow heads). C) Claudin 7 immunoreactivity (red) is 
also affected by TGFB1-exposure in a similar pattern as that of occludin. Results shown are 
representative of 5 paired observations (cells isolated from 5 boars). 
The possibility that TGFB1 exposure and signaling induce cellular changes that result in 
decreases in the abundance of tight junction proteins in 1oPVDs was tested. Results from western 
blot analyses targeting occludin and claudin 7 and respective densitometry indicate that no 
detectable changes in abundance of these proteins occur after 72 hours exposure (Fig. 4). 
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Figure 2.4 TGFB1 exposure (100 ng/ml for 72 hours) does not alter occludin or claudin 7 
abundances in whole cell lysates derived from 1ºPVD monolayers.  
Western blot membranes probed with antibodies targeting occludin (65 kDa), claudin 7 (22 kDa) 
and actin (42 kDa) revealed bands of expected mobilities (arrows) that had no discernable 
intensity differences. Digitized images were subject to densitometry and the summarized 
outcome (bar chart) supports that no changes in the abundances of these proteins occur after 
TGFB1 exposure. Results shown are representative of 6 paired observations (cells isolated from 
6 boars). 
Together with the results from the functional assays, these outcomes suggest that, if 
TGFB1 becomes bioavailable to receptors at vas deferens epithelial cells, it will increase 
permeability across this epithelium by inducing tight junction dissociations. 
TGFBR1 is expressed in apparent high abundance in native vas deferens epithelium 
          To test for the presence and localization of the TGFBR1 in native vas deferens, western 
blot and immunohistochemistry coupled to confocal microscopy were conducted. Prominent 
single bands were evident in lanes loaded with whole vas deferens tissue lysates (Fig. 5). Lanes 
loaded with 1oPVD cell lysates or lysate derived from the NMuMG cell line also exhibited the 
equivalent bands but were much fainter (data not shown). A distinct immunochemical signal was 
also detected on transverse sections of porcine vas deferens. TGFBR1-immunoreactivity was 
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present in virtually all principal cells of the native epithelium and was localized at the apical 
border of the epithelium (Fig. 5). 
 
Figure 2.5 TGFBR1 is expressed apically in native vas deferens epithelium.  
Western blot analyses (left panels) revealed a single band of expected mobility (predicted 56 kDa 
porcine protein, arrow) on lanes loaded with vas deferens tissue lysates (lanes 1-4). No bands 
were detected on lanes loaded with tissue lysates derived from skeletal muscle (lanes 5-7). Actin 
immunoreactivity was employed as a loading control and is shown on left bottom panel. Protein 
lysates were derived from different boars (n = 4 vasa deferentia and 3 muscle samples). Results 
from dual-labeling immunohistochemical analyses (panel on right, top) demonstrate that 
TGFBR1-immunoreactivity (green) is localized at the apical border of the native epithelium. By 
employing occludin immunoreactivity (red) as a reference, these results suggest that the 
TGFBR1 is localized largely at the epithelial brush border. No immunoreactive signals are 
detected if primary antibodies are subtracted from the preparation (lower panel on right). DAPI-
stained nuclei are seen in blue. (n = 3, tissues derived from 3 different boars). L indicates 
“lumen”. 
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These results suggest that TGFB signaling can occur in the native vas deferens 
epithelium and potentially lead to the effects observed in cultured vas deferens epithelial cells. 
 
MAPK11 inhibition has no significant effect on TGFB1-induced decreases in 
transepithelial resistance across vas deferens epithelial cells 
Studies addressing TGFB signal transduction in Sertoli cell primary cultures have 
demonstrated that mitogen-activated protein kinase 11 (MAPK11, also known as p38-MAPK) 
has a prominent role in mediating this signaling [31]. Thus, we tested whether inhibition of this 
kinase could prevent TGFB1-induced decreases in Rte across 1ºPVDs. Consistent again with 
initial experiments, TGFB1-exposed 1ºPVDs (100 ng/ml for 72 hours) exhibited a near total loss 
of Rte. Monolayers exposed to a combination of TGFB1 and the MAPK11 inhibitor SKF86002 
(10 µM) also exhibited drastic decreases of Rte (Fig. 6A). Although SKF86002-treated 
monolayers had Rte means that were approximately twice that of 1ºPVDs exposed to TGFB1 
alone, the increment observed with the MAPK11 inhibitor only approached statistical 
significance (P<0.08). A subsequent set of assays was conducted based on similar experimental 
design, but TGFB1 exposure was restricted to 5 ng/ml for 24 hours. TGFB1-treated 1ºPVDs had 
70% less Rte when compared to untreated monolayers (Fig. 6B). TGFB1 plus SKF86002-treated 
monolayers again, on average, had Rte that remained greater than that of TGFB1-only, but their 
differences were not statistically significant (P<0.06). To test if 10 µM SKF86002 induced 
significant MAPK11-inhibition, we conducted an assay in which Cos-7 cells were cultured in the 
presence or absence of anisomycin (25 µg/ml) and SKF86002 (10 µM). Localization and 
abundance of phosphorylated MAPK11 (pMAPK11) were then accessed via 
immunofluorescence detection and scanning confocal microscopy, which employed a primary 
antibody known to be selective for pMAPK11 [32]. Untreated Cos-7 cells exhibited no 
discernable pMAPK11 immunoreactivity, while anisomycin-treated presented marked nuclear 
pMAPK11 immunoreactivity, and anisomycin plus SKF86002-treated cells had significantly less 
pMAPK11-immunoreactivity than anisomycin-treated (data not shown). 
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Figure 2.6 Pharmacological inhibition of mitogen-activated protein kinase 11 (MAPK11) 
does not prevent TGFB1-induced decreases in Rte across 1ºPVDs.  
A) RTE is severely reduced after 72 hours exposure to TGFB1 (100 ng/ml) and SKF86002 (10 
µM). B) MAPK11 inhibition by SKF86002 (10 µM) also fails to prevent RTE-decreases after 24 
hours exposure in which TGFB1 concentration was 5 ng/ml. n = 6 in A, and 11 in B. 
Collectively, these outcomes suggest that MAPK11 has a marginal role in the TGFB 
signaling events leading to decreases in RTE across vas deferens epithelial cells. MAPK11 seems 
to be expressed in 1oPVDs, to be phosphorylated downstream from TGFBRs activation, but its 
effect in promoting tight junction disruption is suggestively secondary. 
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Discussion 
The goal of this study was to determine what effects, if any, TGFB exerts on epithelia 
lining the vas deferens. Outcomes reported here support a scenario in which activation of TβRs 
expressed in vas deferens epithelia leads to a severe loss in electrical barrier resistivity, while 
anion secretion can also be affected. Furthermore, losses in barrier function were associated with 
disruptions in epithelial tight junction protein organization and/or localization. These data are 
novel and demonstrate that a better understanding of the relationship between TGFB signaling 
and the physiology of cells lining the male excurrent duct is needed. Moreover, these data and 
the known fibrogenic effects of TGFB [17, 33] suggest that this signaling pathway may 
participate in the etiology of human diseases of the male reproductive duct such as epididymal 
and vas deferens obstructions and congenital bilateral absence of the vas deferens. It is also 
thought that breaches in the male barrier can promote the synthesis of anti-sperm antibodies, 
which are arguably responsible for poor spermatozoa motility and male infertility [34].  
Our results show that high levels of barrier resistivity exhibited by cultured vas deferens 
epithelia are virtually eliminated via selective TGFB-receptor activation. Rte was decreased over 
time and by 72 hours it was nearly undetectable. Such severe loss of functional parameters is 
consistent with TGFB-induced EMT [18, 33]. Although these data reveal a high degree of 
vulnerability to the effects of this growth factor, it remains to be determined the magnitude of in 
vivo TGFB signaling in vas deferens epithelia and in epithelial cells lining other segments of the 
male excurrent duct in either physiological or pathological conditions. It is likely that, in a 
physiological context, the effective concentration of active TGFB is less than in the conditions 
employed in these assays. It is possible that, in vivo and under physiological conditions, the 
concentration of active TGFB is low enough to have minimal effects on barrier resistivity. Under 
physiological conditions, TGFB signaling is known to induce an inhibitory effect on tissue 
growth, therefore generating a local tumor-suppressive effect rather than a tumor- or fibrosis-
promoting effect [35, 36]. However, epithelial tissues can develop resistance to TGFB’s growth-
inhibitory effect and switch to a state in which TGFB promotes pathological EMT and tumor 
formation and/or metastasis [37]. Tumors of primary growth in the vas deferens or epididymis 
are extremely rare [38, 39] and this is consistent with the possibility that signaling pathways may 
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exist in these tissues to prevent abnormal tissue growth. Moreover, signaling by TGFB is known 
to induce an anti-inflammatory effect [40]. Thus, it is possible that this signaling reduces 
inflammatory responses to spermatozoa present in the excurrent duct luminal environment [26, 
33]. Nevertheless, the results presented in this study suggest that the potential exists for induction 
of pathological processes by activation of the TGFB signaling pathway in vas deferens epithelia. 
Immunohistochemical results suggest that TGFB receptor activation leads to disruptions 
in epithelial barrier organization and the localization of proteins that form tight junctions, which 
could account for the reduction in Rte. While greater concentration and longer duration of 
exposure revealed profound loss of occludin and claudin 7 from tight junctions, 
immunoreactivity of these proteins were likewise altered in 1ºPVDs exposed to 5 ng/ml for 24 
hours, which was also accompanied by substantial losses in barrier function (70-95%) measured 
electrically. Abnormalities in occludin immunoreactivity included hemi-strands detected along 
the apical aspect of neighboring cells. This outcome seems to suggest that a mechanism for 
dissociation of tight junctions in vas deferens epithelia begins with a length-wise dissociation of 
the tight junction strand, which ‘unzips’ the junctional complexes. Corroborating this possibility 
are reports indicating that TβRI is structurally linked to occludin at tight junctions, and that 
TGFBRs binding and phosphorylation lead to tight junction dissociations [19-21]. Moreover, the 
degree of disruption in occludin and claudin 7 organization was proportional to the level of 
TGFB-exposure, suggesting that increases in local availability of active TGFB in vivo would 
cause increasing levels of disruption to the vas deferens epithelial barrier. Immunohistochemical 
results obtained with the claudin 7 antibody revealed more background immunoreactivity and the 
signal from tight junction strands was less sharp than that obtained with the anti-occludin. This 
may have contributed to the lack of visualization of the length-wise tight junction strand 
dissociation that was typically detected with the anti-occludin antibodies. 
Outcomes reported here also reveal that TGFBR1 immunoreactivity is markedly present 
in the apical border of the native porcine vas deferens epithelium. This supports that these 
epithelia are subject to endogenous signaling if TGFB becomes bio-available at the luminal fluid. 
No definite evidence is yet available on whether vas deferens epithelial cells synthesize and 
secrete TGFB, but immunohistochemical data are available to support that epididymal epithelia 
does [28]. Moreover, local activation of TGFB is a key regulatory mechanism for signaling [41, 
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42] and, interestingly, epididymal epithelia express proteases that activate TGFB [43, 44]. The 
luminal environment of the male excurrent duct also presents segmental pH variability which, in 
segments such as the cauda epididymis, reaches fairly acidic levels. In the healthy duct, one 
would expect duct luminal pH levels that are more alkaline than those required to activate latent 
TGFB [45]. However, in pathologies such as cystic fibrosis there may be increased TGFB 
activation as bicarbonate secretion is thought to be impaired. 
MAPK11 mediates changes in barrier function induced by TGFB3 in Sertoli cells [31] 
and was shown to mediate TGFB-signaling independently in other cell systems [46]. In addition, 
fundamental barrier function differences exist between Sertoli cell primary cultures and 1ºPVDs: 
Rte levels are in the order of 60 [31] and >4,000 Ohms/cm2, respectively. Nevertheless, in Sertoli 
cell primary cultures, MAPK11 inhibition prevented TGFB3-induced Rte decreases by 50% [31]. 
In 1ºPVDs, MAPK11 inhibition reduced the effect of TGFB1 on Rte by 18% and Rte values were 
not significantly rescued from a statistical perspective. These outcomes suggest that TGFB1-
induced Rte-decrease in vas deferens epithelial cells is largely independent of MAPK11. These 
results, considered together with the apparent tight junction dissociation effect, seems to suggest 
that a transcription-independent mechanism, as was shown to occur in the NMuMG cell line 
[19], may account for the extensive barrier function decreases detected in 1oPVD exposed to 
TGFB1. As demonstrated in NMuMG cells, receptor complex formation at tight junctions and 
subsequent Par-6 phosphorylation induces binding of the E3 ubiquitin ligase SMURF1. This 
leads to ubiquination and degradation of RHOA, and tight junction dissociations [19]. It remains 
an open question whether this mechanism is present in epithelia lining the male excurrent duct. 
In summary, this study demonstrates that TGFBR activation in vas deferens epithelia can 
impair epithelial integrity and function. Specifically, the epithelial barrier to small solute 
movement becomes virtually absent. This is expected to compromise generation and 
maintenance of a luminal microenvironment conducive to spermatozoa maturation and male 
fertility. 
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Abstract 
The goal of this study was to determine whether transforming growth factor β1 (TGF-β1) affects 
epithelial cells lining the vas deferens, an organ that is universally affected in cystic fibrosis male 
patients. In PVD9902 cells, which are derived from porcine vas deferens epithelium, TGF-β1 
exposure significantly reduced short circuit current (Isc) stimulated by forskolin or a cell 
membrane-permeant cAMP analog, 8-pCPT-cAMP, suggesting that TGF-β1 affects targets of 
the cAMP signaling pathway. Electrophysiological results indicated that TGF-β1 reduces the 
magnitude of current inhibited by cystic fibrosis transmembrane conductance regulator (CFTR) 
channel blockers. Real-time RT-PCR revealed that TGF-β1 down-regulates the abundance of 
mRNA coding for CFTR, while biotinylation and western blot showed that TGF-β1 reduces both 
total CFTR and apical cell surface CFTR abundance. These results suggest that TGF-β1 causes a 
reduction in CFTR expression, which limits CFTR-mediated anion secretion. TGF-β1 associated 
attenuation of anion secretion was abrogated by SB431542, a TGF-β1 receptor I inhibitor. 
Signaling pathway studies showed that the effect of TGF-β1 on Isc was reduced by SB203580, an 
inhibitor of p38 mitogen-activated protein kinase (MAPK). TGF-β1 exposure also increased the 
amount of phospho-p38 MAPK substantially. In addition, anisomycin, a p38 MAPK activator, 
mimicked the effect of TGF-β1, which further suggests that TGF-β1 affects PVD9902 cells 
through a p38 MAPK pathway. These observations suggest that TGF-β1, via TGF-β1 receptor I 
and p38 MAPK signaling, reduces CFTR expression to impair CFTR-mediated anion secretion, 
which would likely compound the effects associated with mild CFTR mutations, and ultimately 
would compromise male fertility. 
Key words: TGF-β1, vas deferens epithelial cells, male infertility, CFTR, p38 MAPK 
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Introduction 
Transforming growth factor beta 1 (TGF-β1), the predominant isoform of TGF-β, is a pleiotropic 
cytokine regulating cell proliferation and apoptosis, differentiation, inflammation, extracellular 
matrix synthesis, and developmental processes (6). TGF-β1 signals through binding to a cell 
surface type II serine/threonine kinase receptor, which then recruits and activates the type I 
receptor. Intracellular signal transduction is most commonly mediated through the canonical 
Smad pathway, although several non-canonical kinase-mediated pathways (PI3K, Erk, JNK, and 
p38 MAPK) have been implicated (6, 11). Such components of the activated signaling cascades 
(whether Smads or protein kinases) translocate into the nucleus and alter gene expression to 
regulate multiple cellular functions. 
Altered expression of TGF-β1 has been involved in fibrotic diseases including cystic fibrosis, a 
life-shortening disease affecting 1 in every 2,000 – 3,000 newborn Caucasians (7, 9). Cystic 
fibrosis affects many organ systems including the respiratory, gastrointestinal, musculoskeletal, 
and reproductive systems. It is associated with variations in the sequence of CFTR, the gene 
coding for the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR mutations 
lead to the reduction or absence of functional CFTR protein in the apical membrane of epithelial 
cells throughout the body, which results in attenuated anion secretion across epithelial tissues. 
The clinical severity of cystic fibrosis is determined not only by the type of CFTR mutation(s) 
carried by the patient but also by genetic modifiers (7). Genotyping results suggest that cystic 
fibrosis patients with a TGF-β1 ‘high producer’ genotype for codon 10 are associated with a 
more severe lung disease as well as a more rapid deterioration in lung function (1, 12). 
Additionally, measurement of plasma TGF-β1 levels suggests that higher concentrations of TGF-
β1 are correlated with increased severity of lung disease in pediatric cystic fibrosis patients (16). 
All these observations indicate that elevated levels of circulating TGF-β1 lead to worse cystic 
fibrosis lung disease. 
In cystic fibrosis male patients, vas deferens and epididymis are the most frequently affected 
tissue and these tissues undergo anatomical disruptions early in life. About 98% of male cystic 
fibrosis patients are infertile due to congenital bilateral absence of the vas deferens (CBAVD), a 
condition characterized by duct atresia and post-testicular azoospermia (10, 47). Besides a 
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population of ~30,000 cystic fibrosis patients in the United States and ~70,000 worldwide, about 
one in every 25 Caucasians are carriers of disease-associated CFTR sequences. Cystic fibrosis 
carriers will not be diagnosed by the sweat test and do not have apparent cystic fibrosis 
symptomology, but they are associated with a higher frequency of infertility (27). Genotypic 
analysis revealed no apparent correlation between CBAVD in European populations and two 
distinct single nucleotide polymorphisms in the TGF-β1 gene (17). However, no study has 
focused on whether TGF-β1 affects vas deferens epithelium. It is possible that TGF-β1 
attenuates vas deferens epithelial anion secretion in cystic fibrosis carriers who are associated 
with mild disease or with no typical symptomology, and would promote cystic fibrosis-related 
pathology. 
The objective of the current study was to determine whether TGF-β1 impairs ion transport across 
cultured vas deferens epithelial monolayers. PVD9902, a cell line that was derived from porcine 
vas deferens epithelium and recapitulates most ion transport characteristics of freshly isolated 
porcine vas deferens epithelial tissue, was used (5). Electrophysiological, molecular, and 
immunological assays were performed to evaluate the changes in PVD9902 cells when exposed 
to TGF-β1. Experiments were focused to elucidate the potential mechanisms by which TGF-β1 
affects vas deferens tissue. 
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Materials and Methods 
Chemicals. Forskolin (Coleus forskohlii) was obtained from Calbiochem (La Jolla, CA). GlyH-
101 was obtained from Millipore (Billerica, MA). N-[4-methylphenylsulfonyl]-N’-[4-
trifluoromethylphenyl] urea (DASU-02) was synthesized in the laboratory. Unless indicated 
otherwise, chemicals used were purchased from Sigma-Aldrich, Inc. (St. Louis, MO). 
Cell culture. PVD9902 cells (5) were seeded onto plastic 25-cm2 cell culture flasks (Corning, 
Inc., Corning, NY) and grown in Dulbecco’s modified Eagle medium (DMEM, Invitrogen, 
Carlsbad, CA) supplemented with 10% heat inactivated fetal bovine serum (FBS, Atlanta 
Biologicals, Atlanta, GA) and 1% penicillin and streptomycin (Invitrogen) in a humidified 5% 
CO2 incubator at 37°C. Confluent cells were washed with phosphate buffered saline (PBS), lifted 
by trypsin-EDTA (0.25%, Invitrogen), seeded onto permeable supports (Snapwell or Transwell, 
Costar, Corning, Inc.), and cultured for 14 days prior to experimental assay. Media were 
refreshed every other day and monolayers were exposed to TGF-β1 (5 ng/ml, R&D Systems, 
Minneapolis, MN) in the basolateral compartments for the last 24 hours prior to assay. 
Electrophysiology. PVD9902 monolayers were mounted in modified Ussing-style chambers 
(model DCV9, Navicyte, San Diego, CA), bathed symmetrically with Ringer solution 
(composition in mM: 120 NaCl, 25 NaHCO3, 3.3 KH2PO4, 0.83 K2HPO4, 1.2 MgCl2, and 1.2 
CaCl2), maintained at 39°C and bubbled with 5% CO2-95% O2. After recording open circuit 
potential, monolayers were clamped to 0 mV, and a 5-second bipolar pulse was applied every 
100 seconds using a voltage clamp (model 558C-5, University of Iowa, Dept. of Bioengineering, 
Iowa City, IA). Short circuit current (Isc), which represents transepithelial electrogenic ion 
transport, was monitored and recorded at 1 Hz with an Intel based computer and MP100A-CE 
interface (v.3.2.6, BIOPAC Systems, Santa Barbara, CA). The change in current in response to 
the periodic voltage pulse was used to calculate transepithelial electrical resistance using Ohm’s 
law (Rte = ∆V/∆Isc). Test reagents were added to the apical and/or basolateral side(s) of each 
chamber as indicated. The magnitude of test reagent-stimulated Isc was determined by ∆Isc 
between the pre-addition Isc value and the peak value within first 10 minutes after addition.  
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RNA isolation and real-time RT-PCR. RNA was isolated from PVD9902 monolayers using 
an RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. RNA 
quantity was determined spectrophotometrically (ND 8000, NanoDrop Products, Wilmington, 
DE) while RNA quality was confirmed using microfluidics (Bioanalyzer, Agilent Technologies, 
Santa Clara, CA). Ten nanograms of RNA were used as template and RT-PCR was performed 
using the iScript One-Step RT-PCR Kit with SYBR Green (Bio-Rad, Hercules, CA) with 
specific primer pairs. The sequences of primer pairs were as follows: CFTR (forward) 5’-CCG 
GGC ACC ATT AAA GAA AAC-3’ and (reverse) 5’-GCC ATC AAT TTA CGA ACA CGG 
C-3’ (29); 18s (forward) 5’-GAG GTT CGA AGA CGA TCA GA-3’ and (reverse) 5’-TCG CTC 
CAC CAA CTA AGA AC-3’ (49). Relative quantification of mRNA was conducted by a 
SmartCycler (Cepheid, Sunnyvale, CA) using the ∆∆Ct method with 18s as the reference, in 
which ∆Ct=Ct(Vehicle)-Ct(Treated), ∆∆Ct=∆Ct(Target)-∆Ct(Reference); the change in copy number of 
target RNA relative to reference RNA=2∆∆Ct. The quality of RT-PCR products was validated by 
a single peak melt curve, which represents single PCR product, and by a single band of expected 
mobility in a 1.5% agarose DNA gel. The cDNA was visualized by inclusion of ethidium 
bromide (1 µg/ml) and the product size was determined by a 100-bp DNA ladder (Promega, 
Madison, WI). 
Biotinylation and immunoblotting. PVD9902 monolayers were homogenized and lysed with 
Laemmli sample buffer (2X) containing 4% SDS, Tris-HCl (125 mM) and protease inhibitors 
(Roche Diagnostics, Indianapolis, IN). Lysates were passed through 25-gauge needles repeatedly 
and then centrifuged at 14,000 g for 10 minutes. Supernatant protein concentrations were 
determined by measuring absorbance at 280 nm (A280). Collected supernatants were then mixed 
with bromophenol blue (0.01% w/v), glycerin (10%), and DTT (0.1 M) and the mixtures were 
incubated at 37°C for 2 hours. Equal amounts of protein from each treatment were loaded to 8-
16% Tris-HEPES-SDS gradient gels (Pierce, Rockford, IL). Following electrophoresis, proteins 
were transferred onto Immobilon-P transfer membrane (Millipore). Membranes were blocked 
with 5% nonfat dry milk (Bio-Rad) in PBS with 0.1% Tween-20 for 2 hours and then probed 
with primary antibodies: anti-CFTR (Millipore, 05-583), anti-phospho-p38 MAPK (Cell 
Signaling, 4511, Danvers, MA), and anti-actin (Sigma-Aldrich, A2066) overnight at 4°C, 
incubated in peroxidase-conjuated secondary antibodies (Pierce) for 1 hour, followed by 
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development using chemiluminiscent substrates (Super Signal West Pico and Femto, Pierce). 
Images were obtained digitally (Kodak Image Station 4000 R, Kodak, Rochester, NY) and 
quantification was performed by measuring band signal intensity (UN-SCAN-IT Gel, Silk 
Scientific, Inc, Orem, Utah). 
For the detection of membrane proteins, filter-grown PVD9902 monolayers were washed and 
incubated with Ringer solution at 37°C for 30 minutes, and then placed on ice. Biotinylation 
reagent containing sulfo-NHS-SS-biotin (400 μM, Pierce) in Ringer solution was added to the 
apical or basolateral compartment for 15 minutes. After biotin incubation, monolayers were 
rinsed and washed 3 times with Ringer solution containing 50 mM glycine to quench unreacted 
sulfo-NHS-SS-biotin groups. After removing quenched biotin, PVD9902 monolayers were lysed 
and homogenized. Supernatants were incubated with immobilized neutravidin-agarose (Pierce) 
setting in micro-spin columns (Pierce) for 2 hours at room temperature. Non-bound proteins 
were collected as flow-through samples. Avidin gels were washed 3 times with lysis buffer and 
incubated with Laemmli buffer containing DTT (50 mM) to elute bound biotinylated proteins. 
Immunoblotting was completed as indicated previously to detect cell surface labeling. 
Lactate dehydrogenase (LDH) assay. The activity of LDH released from damaged cells into 
the culture medium was measured using the LDH cytotoxicity detection kit (CytoTox-ONE; 
Promega Corp., Madison, WI). PVD9902 cells were seeded at a density of 1×105 cells per well 
onto sterile 96-well opaque-walled tissue culture plates (Nalge Nunc International Corp., 
Rochester, NY), cultured for 72 hours, treated with vehicle or TGF-β1 (5 ng/ml) for 24 hours, 
and incubated with CytoTox-ONE reagent according to the manufacturer’s instructions. Lysis 
solution was added to cells in paired wells to determine maximal LDH release in “lysed” cells. 
The fluorescence values were recorded to determine LDH activity and to estimate the number of 
damaged cells.  
Data analysis. All numerical results are reported as mean ± SEM. Calculations, t-tests, and 
graphs were performed with Sigmaplot (v 10.0, SPSS Inc, Richmond, CA) and Excel 2007 
(Microsoft Corp, Redmond, WA). 
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Results 
TGF-β1 impairs cAMP-stimulated anion secretion across PVD9902 monolayers. 
Paired vehicle- or TGF-β1-treated PVD9902 monolayers were mounted in modified Ussing-style 
chambers for measurements of Rte and Isc. Ussing chamber assays also included in-chamber 
pharmacological tests and any acute responses were visualized and recorded in real time. Both 
vehicle and TGF-β1 treated PVD9902 cells formed electrically tight epithelial monolayers. TGF-
β1 exposure was associated with lower Rte when compared to paired monolayers exposed to 
vehicle (Table 1) although the difference did not reach statistical significance (P>0.18). 
Forskolin (2 μM), an adenylyl cyclase activator that increases intracellular cAMP generation, 
was employed to stimulate cAMP-dependent anion secretion (26, 28). Typically, forskolin 
exposure elicited a transient peak in Isc followed by a sustained plateau, indicating ongoing anion 
secretion (Figure 1). In TGF-β1 treated monolayers the response to forskolin followed the same 
pattern but was reduced to less than half of the typical magnitude. The forskolin-induced 
increase in Isc was associated with decreased Rte, suggesting the activation of channels that 
contribute to anion secretion. In vehicle treated PVD9902 monolayers, forskolin exposure 
induced a reduction of 6096 ± 1174 Ω cm2 in Rte while in TGF-β1 treated monolayer, the 
reduction in Rte was significantly less (1799 ± 460 Ω cm2).  
Table 3.1 Basal transepithelial electrical resistance (Rte) of PVD9902 cells after different 
treatments. 
Treatment Basal Rte, Ω cm2 
Vehicle  8,184 ± 477 
TGF-β1  6,721 ± 803 
Vehicle + SB431542  3,923 ± 657 
TGF-β1 + SB431542  4,635 ± 783 
Vehicle + SB203580  6,731 ± 580 
TGF-β1 + SB203580  4,822 ± 683 
Anisomycin  4,123 ± 1,026 
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Figure 3.1 TGF-β1 impairs forskolin-stimulated anion secretion across PVD9902 
monolayers.  
A) Representative Ussing chamber recordings of vehicle or TGF-β1 treated (5 ng/ml, 24 hours) 
PVD9902 monolayers exposed to forskolin (2 μM). The dashed lines represent the reference 
point of zero net current, indicating no net ion flux. Bar indicates the duration of symmetrical 
forskolin exposure. B) Summarized results of forskolin-stimulated anion secretion from 7 paired 
experiments. Asterisk (*) indicates significant difference between vehicle and TGF-β1 treated 
monolayers (P<0.05). 
Isobutylmethylxanthine (IBMX, 100 μM), a non-selective cyclic nucleotide phosphodiesterase 
inhibitor, was added before and with forskolin during some experiments to preclude cAMP 
breakdown and maximize cytosolic cAMP accumulation. IBMX elicited an immediate increase 
in Isc, which suggests that the PVD9902 cells have ongoing cyclic nucleotide turnover at rest, 
and subsequent exposure to forskolin further increased anion secretion (Figure 2). Although 
PVD9902 monolayers exposed to TGF-β1 responded to both IBMX and forskolin with an 
increase in Isc, the response to both was significantly muted, suggesting that reduced cytosolic 
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cAMP concentration in cells exposed to TGF-β1 did not likely account for the differences in 
outcome. Results from experiments using a membrane-permeant cAMP analog, 8-pCPT-cAMP, 
to stimulate Isc showed that TGF-β1 also reduces these responses (Figure 3). Taken together, 
these outcomes suggest that a downstream component(s) of the cAMP signaling pathway or an 
ion transport protein(s) is negatively impacted by TGF-β1 exposure.  
 
Figure 3.2 TGF-β1 impairs anion secretion across PVD9902 monolayers stimulated by 
forskolin in the presence of IBMX.  
A) Representative current recordings of vehicle or TGF-β1 treated (5 ng/ml, 24 hours) PVD9902 
monolayers exposed to IBMX (100 μM) followed by forskolin (2 μM) as indicated by the 
labeled bars. B) Results summarized from 4 paired experiments comparing the responses to the 
combination of IBMX and forskolin. Asterisk (*) indicates statistical difference from vehicle 
(P<0.05). 
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Figure 3.3 TGF-β1 impairs 8-pCPT-cAMP-stimulated anion secretion across PVD9902 
monolayers.  
A) Ussing chamber traces of vehicle or TGF-β1 treated (5 ng/ml, 24 hours) PVD9902 
monolayers in response to 8-pCPT-cAMP (300 μM) are shown. B) Summary of responses to 8-
pCPT-cAMP from 5 paired experiments. Asterisk (*) indicates statistical significance (P<0.05). 
To test more directly for TGF-β1-induced changes CFTR-mediated anion secretion, cells were 
exposed to selective CFTR channel blockers after the sustained response to forskolin had been 
established. In both vehicle and TGF-β1 treated monolayers, DASU-02 (100 μM) inhibited 
~40% of forskolin-stimulated Isc (Figure 4A). However, in vehicle treated PVD9902 monolayers, 
the absolute value of Isc inhibited by DASU-02 was more than 2 fold of the Isc in TGF-β1 treated 
PVD9902 monolayers. Another CFTR selective blocker, GlyH-101, was tested, also. Similar to 
the effect of DASU-02, GlyH-101 (10 μM) inhibited forskolin-stimulated Isc in both vehicle and 
TGF-β1 treated monolayers. The magnitude of Isc blocked by GlyH-101 in TGF-β1 treated 
monolayers was much less than in monolayers exposed to vehicle alone (Figure 4B). The 
attenuated effect of both DASU-02 and GlyH-101 on TGF-β1 treated monolayers, together with 
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a less profound reduction in Rte stimulated by the activation of cAMP-mediated pathway (see 
Figure 1A), suggest that TGF-β1 exposure reduces CFTR-mediated ion transport. 
 
Figure 3.4 TGF-β1 reduces the effect of CFTR inhibitors.  
Typical current recordings of vehicle or TGF-β1 treated (5 ng/ml, 24 hours) PVD9902 
monolayers exposed sequentially to forskolin (2 μM) followed by A) DASU-02 (100 μM) or B) 
GlyH-101 (10 μM). C) Summarized results of CFTR inhibitor blocked anion secretion from 5-6 
paired experiments. Asterisk (*) indicates statistical difference from vehicle (P<0.05). 
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TGF-β1 down-regulates CFTR mRNA expression. 
Real-time RT-PCR was performed using RNA isolated from 5 paired monolayers of different 
passage numbers to detect the relative abundance of mRNA coding for CFTR. The Ct value for 
CFTR in vehicle treated PVD9902 cells was 28.9 ± 0.4 while the Ct value of CFTR in TGF-β1 
treated cells was 29.8 ± 0.6. For the reference gene 18s, the Ct values in vehicle treated and 
TGF-β1 treated cells were virtually equal, 12.7 ± 0.3 and 12.8 ± 0.3 for vehicle and TGF-β1 
treatments, respectively (Figure 5). Using the ∆∆Ct method, the relative abundance of mRNA 
coding for CFTR in TGF-β1 treated cells was 60.2% ± 8.4% of its abundance in cells exposed to 
vehicle, indicating that TGF-β1 down-regulates CFTR mRNA expression. 
 
Figure 3.5 TGF-β1 down-regulates CFTR mRNA abundance.  
Expression of mRNA coding for CFTR in PVD9902 monolayers exposed to vehicle or TGF-β1 
(5 ng/ml, 24 hours) was determined by real-time RT-PCR. Data are summarized from 5 paired 
experiments and are expressed as the ∆Ct between vehicle treated cells and TGF-β1 treated cells 
for the reference, 18s and for CFTR. Asterisk (*) indicates significant difference (P<0.05). 
TGF-β1 down-regulates CFTR protein expression. 
Given the electrophysiological evidence that TGF-β1 impairs anion secretion through CFTR as 
well as the RT-PCR outcomes that TGF-β1 down-regulates the copy number of CFTR mRNA, 
western blot analysis was performed to detect whether TGF-β1 affects the apparent protein 
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expression of CFTR using an antibody that detects CFTR in primary adult and neonatal porcine 
vas deferens epithelial cells at the same mobility as in Calu-3 cells (35). Typically, CFTR is 
observed following electrophoresis in 3 different isoforms, namely A-band, B-band, and C-band, 
that exhibit distinct mobilities due to the extent of post-translational modification (32). A-band 
represents nascent CFTR protein lacking glycosylation, B-band represents CFTR with core 
glycosylation, and C-band represents the mature fully glycosylated form. Both B-band and C-
band isoforms were identified by western blot in PVD9902 cells, whereas A-band was not 
detected (Figure 6A). CFTR protein expression was quantified by densitometry and then 
normalized to an internal loading control, β-actin. The relative abundance of CFTR following 
TGF-β1 exposure was then normalized to vehicle monolayers. Summarized immunoblotting 
results suggest that TGF-β1 exposure led to a significant reduction of the abundance of CFTR 
protein for both B-band and C-band isoforms (Figure 6A). 
Cell surface biotinylation together with western blot analysis were applied to investigate whether 
TGF-β1 exposure also would decrease apical cell surface CFTR protein expression. PVD9902 
monolayers were biotinylated from the apical compartment or from the basolateral compartment. 
All fractions were subjected to SDS-PAGE followed by western blot analysis. Occludin, a tight 
junction protein that can be biotinylated from both apical and basolateral compartments, was 
used to verify unilateral biotin labeling of proteins in either the apical or basolateral membrane in 
each experiment (data now shown). Results show that CFTR is detected in apical biotinylated 
cell lysate and flow through but not in basolateral biotinylated cell lysate, which suggests that 
CFTR exists in the apical cell surface and exists intracellularly, but not in the basolateral cell 
surface (Figure 6B). Similar to the outcomes in Figure 6A, in the whole cell lysate of TGF-β1 
treated PVD9902 cells, the expression of total CFTR was less than its expression in vehicle 
treated cells. The absolute expression of apical cell surface CFTR in cells exposed to TGF-β1 
was also less than its apical expression in cells exposed to vehicle alone. Additionally, the 
abundance of apical biotinylated CFTR was compared with the abundance of total CFTR in 
whole cell lysate to evaluate the percentage of apical cell surface CFTR expression. In both 
vehicle treated cells and TGF-β1 treated cells, apical cell surface CFTR accounts for ~16% of 
total CFTR, suggesting that TGF-β1 does not affect the relative expression of apical cell surface 
CFTR (Figure 6B). Taken together, these outcomes suggest that TGF-β1 decreases the total 
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amount of CFTR protein present in the cells as well as its amount in the apical membrane where 
it could contribute to anion secretion. Decreased expression could limit CFTR-mediated anion 
secretion, as was observed. 
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Figure 3.6 TGF-β1 reduces CFTR abundance in cell lysates and in the apical cell surface.  
A) CFTR expression was assessed in whole cell lysates from PVD9902 monolayers exposed to 
vehicle or TGF-β1 (5 ng/ml, 24 hours) by western blots. Densitometric analysis was conducted 
to quantify signal intensity that could be attributed to total CFTR (C band and B band), fully 
glycosylated CFTR (C band), and core-glycosylated CFTR (B band). Data are expressed as 
relative abundance in CFTR normalized to β-actin with respect to vehicle. Data are summarized 
from 4 independent experiments. B) Apical cell surface CFTR expression was determined by 
biotinylation and western blots from PVD9902 monolayers exposed to vehicle or TGF-β1 (5 
ng/ml, 24 hours). Densitometric analysis was conducted to determine protein abundance of total 
CFTR and apical cell surface CFTR. Summarized relative CFTR abundance is from 6 
independent experiments. Asterisks indicate significant reductions when compared to vehicle 
(P<0.05). 
Receptor inhibitor abolishes TGF-β1-induced reduction in anion secretion.  
TGF-β1 activates transmembrane receptors to elicit cytosolic signaling and ultimately to affect 
cellular activity. SB431542 (10 μM), a selective TGF-β1 receptor I inhibitor (14, 25), was added 
into PVD9902 culture media 1 hour prior to TGF-β1 exposure. After 24 hours of TGF-β1 
exposure, PVD9902 cells were mounted into modified Ussing chambers to measure forskolin-
stimulated anion secretion. In PVD9902 monolayers treated with both TGF-β1 and SB431542, 
forskolin elicited a sharp increase in Isc that was significantly greater than monolayers exposed to 
TGF-β1 alone and was not different, statistically, from vehicle alone (Figure 7). The outcome 
that the reduction of forskolin response by TGF-β1 can be abolished by SB431542 indicates that 
TGF-β1 receptor signaling pathway is necessary and sufficient to account for TGF-β1-
suppressed anion secretion across PVD9902 monolayers.  
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Figure 3.7 A TGF-β receptor I inhibitor, SB431542, abolishes the TGF-β1-associated 
reduction in the response to forskolin.  
A) Typical responses to forskolin (2 μM) in PVD9902 monolayers exposed to vehicle, TGF-β1 
(5 ng/ml), SB431542 (10 μM), or TGF-β1 plus SB431542. B) Summary of forskolin-stimulated 
anion secretion from 10-14 experiments. Asterisk (*) indicates statistical difference from vehicle 
(P<0.05). 
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TGF-β1 activates the p38 MAPK signaling pathway in PVD9902 cells.  
Given the observations that TGF-β1 activates its cognate receptor and attenuates CFTR-mediated 
anion secretion, downstream signaling cascades elicited by TGF-β1 were investigated using a 
pharmacological approach. PVD9902 cells were exposed to SB203580, a compound that inhibits 
p38 MAPK catalytic activity (15, 24). PVD9902 monolayers exposed to SB203580 (10 μM) 
exhibited a rapid response to forskolin that is not significantly different from monolayers 
exposed to vehicle along. However, monolayers exposed to TGF-β1 plus SB203580 exhibited a 
significantly higher response to forskolin than monolayers treated with TGF-β1 alone (Figure 8). 
The observation that SB203580 attenuates the effect of TGF-β1 on forskolin stimulated Isc 
provides evidence that p38 MAPK is required for the TGF-β1-induced change in ion transport. 
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Figure 3.8 A p38 MAPK inhibitor, SB203580, attenuates TGF-β1-impaired forskolin 
response. 
A) Typical responses to forskolin (2 μM) in PVD9902 monolayers exposed to vehicle, TGF-β1 
(5 ng/ml), SB203580 (10 μM), or TGF-β1 plus SB203580. B) Responses to forskolin are 
summarized from 4-5 experiments. Asterisks (*) indicate statistical significance (P<0.05). 
 
Western blot analysis was performed to detect phospho-p38 MAPK, which is thought to be the 
active form. Results presented in Figure 9 demonstrate that phospho-p38 MAPK is present in all 
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samples, regardless of TGF-β1 exposure. However, after normalization to β-actin as a loading 
control, the intensity of the phospho-p38 MAPK band was ~1.7 fold in samples from cells 
exposed to TGF-β1 when compared to cells exposed to vehicle. This increase in the relative 
abundance of phospho-p38 MAPK was prevented by the pre-treatment of SB431542, suggesting 
that TGF-β1-induced activation of p38 MAPK signaling pathway is through the activation of 
TGF-β1 receptor. Together with ion transport results showing that p38 MAPK inhibitor 
attenuates the effect of TGF-β1, these outcomes suggest quite strongly that TGF-β1, through the 
activation of its receptor, induces phosphorylation of p38 MAPK and, thus, activates the p38 
MAPK signaling pathway. 
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Figure 3.9 TGF-β1 up-regulates the abundance of phospho-p38.  
The expression of phospho-p38 MAPK was determined by immunoblots and measured by 
densitometric analysis using whole cell lysates isolated from PVD9902 monolayers treated with 
vehicle, SB431542 (10 μM), TGF-β1 (5 ng/ml), or TGF-β1 plus SB431542. The relative 
abundance of phospho-p38 under each treatment is normalized to β-actin with respect to vehicle. 
Summarized data are from 6-12 independent experiments. Asterisks indicate significant 
reductions when compared to vehicle (P<0.05). 
The role of the p38 MAPK signaling pathway in forskolin-stimulated anion secretion was also 
tested by anisomycin, an activator of the p38 MAPK pathway (3, 50). PVD9902 cells were 
exposed to vehicle or anisomycin (2 μg/ml) for 24 hours followed by modified Ussing chamber 
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experiments. Similar as the effect of TGF-β1, anisomycin exposure led to a significant reduction 
in forskolin-stimulated anion secretion compared with paired monolayers (Figure 10). Real-time 
RT-PCR was also performed to identify the effect of anisomycin on CFTR mRNA abundance. 
The ∆Ct value between vehicle and anisomycin treated PVD9902 cells for CFTR was ~-0.4 
while the ∆Ct value for 18s was ~0.05, with a ∆∆Ct value of -0.4 ± 0.2 (Figure 11). These 
outcomes suggested that anisomycin exposure was associated with a 24.0% ± 7.7% reduction in 
mRNA coding for CFTR. These observations show that anisomycin mimics the effect of TGF-β1 
on forskolin response and on CFTR mRNA abundance, which provide further evidence that the 
p38 MAPK signaling pathway is involved in the effect of TGF-β1 on PVD9902 monolayers. 
 
Figure 3.10 A p38 MAPK activator, anisomycin, impairs forskolin-stimulated anion 
secretion across PVD9902 monolayers.  
A) Representative Ussing chamber traces of vehicle or anisomycin treated (2 μg/ml, 24 hours) 
PVD9902 monolayers exposed to forskolin (2 μM). B) Summarized results of forskolin-
stimulated anion secretion from 11 paired experiments. Asterisk (*) indicates statistical 
difference from vehicle (P< 0.05). 
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Figure 3.11 Anisomycin down-regulates CFTR mRNA abundance.  
CFTR mRNA abundance in PVD9902 monolayers exposed to vehicle or anisomycin (2 μg/ml, 
24 hours) was determined by real-time RT-PCR. Data are summarized from 4 paired 
experiments and are expressed as the ∆Ct between vehicle treated cells and anisomycin treated 
cells for 18s and for CFTR. Asterisk (*) indicates significant difference (P<0.05). 
TGF-β1 does not affect the viability of PVD9902 cells. 
Another mechanism that can explain the reduction of anion secretion induced by TGF-β1 is that 
TGF-β1 leads to cell death and thus reduces the number of cells present in the monolayer. This 
mechanism, however, is unlikely based on the Rte measured at the outset of Ussing chamber 
experiments (Table 1). PVD9902 monolayers exposed to TGF-β1 exhibited a high basal Rte that 
was not different, statistically, from vehicle. Additional evidence was gathered by measuring 
LDH release to determine whether TGF-β1 compromises cell viability. A commercial kit in 
which florescence is proportional to LDH activity in the cell culture medium was used to 
measure the release of LDH from cells with damaged membranes. PVD9902 cells were cultured 
on 96-well plates to measure the leakage of LDH from cytoplasm into culture medium. Cells 
exposed to TGF-β1 showed an LDH release that was not different from vehicle alone while cells 
exposed to the lysis solution exhibited a remarkable release (Figure 12). This outcome indicates 
that TGF-β1 has no measurable effect on cell viability and thus rule out the possibility that 
reduced anion secretion across PVD9902 monolayers is due to decreased cell numbers. 
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Figure 3.12 TGF-β1 has no detectable effect on lactate dehydrogenase (LDH) release. 
 PVD9902 cells were grown on 96 well plates for three days and then exposed to vehicle or 
TGF-β1 (5 ng/ml, 24 hours). Cells in paired wells were lysed to determine maximum LDH 
activity. LDH activity in the apical medium is proportional to fluorescence at 590 nm. Results 
are summarized from 6 experiments.  
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Discussion 
This study demonstrated that TGF-β1 exposure reduces the secretory response to a variety of test 
reagents that initiate signaling through the cAMP-mediated pathway, including forskolin, the 
combination of forskolin and IBMX, and 8-pCPT-cAMP. Real time RT-PCR, immunoblots, and 
electrophysiological measurements showed that TGF-β1 reduces the relative copy number of 
mRNA coding for CFTR, that less CFTR is expressed, that less CFTR is present in the apical 
cell membrane, and that there is reduced anion secretion attributable to CFTR. Studies focusing 
on the cellular signal transduction mechanisms suggest that TGF-β1 binds to and activates TGF-
β1 receptor I. Receptor activation is associated with an increase in the activity of the p38 MAPK 
signaling pathway as demonstrated by an increase in the phosphorylated form of the enzyme. 
Additional support for this scenario was drawn from experiments in which anisomycin mimicked 
the effect of TGF-β1 on CFTR expression to impaired anion transport across cultured vas 
deferens epithelial cells. These observations define a scenario by which elevated levels of TGF-
β1 could heighten the symptomology of mild cystic fibrosis. 
Previous studies suggested that TGF-β1 modulates epithelial ion transport by changing the 
amount, location or activity of the apical CFTR channel, although none of them has studied the 
effect of TGF-β1 on vas deferens epithelia (18, 19, 38, 39). TGF-β1 exposure led to a significant 
reduction in the magnitude of the response to forskolin or a cAMP analog in colonic epithelia, 
T84 and HT-29 cells, and in kidney epithelia, MDCK cells, by changing the expression and 
distribution of CFTR (18, 19). A similar role of TGF-β1 to reduce cAMP-driven anion secretion 
and CFTR expression has been identified in lung and airway epithelial cells (38, 39). The present 
report demonstrates that TGF-β1 down-regulates the gene expression of CFTR, its protein 
abundance, and especially the protein abundance of functional CFTR in the cell surface. A single 
CFTR channel has a conductance of ~10 pS and a channel open probability of ~0.4 when 
exposed to forskolin (40, 41, 44). If one employs a series of reasonable assumptions that are 
consistent with a previous report (e.g., PVD9902 cells exposed to forskolin have an apical 
membrane driving force of ~4 mV, that there are 400 CFTR channels in apical membranes of 
typical cells, and that there are ~106 cells per monolayer), forskolin exposure will induce an 
increase in Isc of ~6.4 μA, which approximates the magnitude of our observations (Figure 1). 
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Furthermore, if one assumes apical, basolateral and paracellular resistances of 9,000, 8,000, and 
15,000 Ω cm2 in resting conditions, the calculated Rte would be ~8,100 Ω cm2, which is similar 
to what is observed for these cell monolayers. Activation of CFTR by forskolin would decrease 
apical resistance to ~5,900 Ω cm2 and Rte to ~5,500 Ω cm2. A 25% reduction in the number of 
channels would be expected to have no effect on basal Rte, but would reduce forskolin-stimulated 
Isc by 25% and would reduce the forskolin-induced change in Rte by a lesser amount, which again 
is consistent with the observations. These simple calculations support certain inferences. First, 
TGF-β1-attenuated forskolin response is explainable largely by invoking a single change in the 
cells, a reduced number of CFTR channels in the apical membranes. A change in the signaling 
cascade leading to channel activation, the CFTR channel activation mechanism, the channel 
inactivation mechanism, or in maximal channel open probability is not required. However, not 
all observations are fully explained by this mechanism. Notably, one expects a reduction in 
channel number to have no effect on basal Rte. Further, the full magnitudes of the shifts in Rte are 
not fully explained by the difference in channel expression. Initial sets of experiments were 
conducted to test for indications either of cell death or of epithelial to mesenchymal transition. In 
both cases the results were negative. TGF-β1 exposure does not alter the release of LDH, 
suggesting that TGF-β1 does not affect the viability of PVD9902 cells. Outcomes from western 
blots showed that TGF-β1 exposure does not alter the expression of E-cadherin, an epithelial cell 
marker that typically is down-regulated following exposure of epithelial cell types to TGF-β1, 
suggesting that TGF-β1 did not induce epithelial to mesenchymal transition in PVD9902 cells 
(data not shown). Clearly, additional experiments are required to address these observations 
further. Nonetheless, the preponderance of the observed effects can be explained by a TGF-β1 
associated reduction in CFTR expression that requires activation of the TGF-β1 receptor I and 
the p38 MAPK pathway. 
TGF-β1 has been associated with reproductive function and male fertility (20). Male TGF-β1 
null mutant mice exhibited a reduced level of testosterone as well as a complete inability to mate 
with females although the weight and histology of male reproductive tissues, including penis, 
seminal vesicles, and testes, were normal (21). However, the effect of TGF-β1 on vas deferens, 
especially ion transport across vas deferens epithelia, is unknown. It is of critical importance 
since the concentration of TGF-β1 in seminal plasma is 85-238 ng/ml (31, 37), which is much 
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higher than its concentration in plasma or any other bodily fluids (34). These observations, which 
demonstrate that TGF-β1 modulates ion transport across cultured vas deferens epithelial 
monolayers, extend our understanding of the physiological and/or pathological roles of TGF-β1 
in vas deferens and in male fertility. 
Vas deferens epithelia express numerous ion channels and transporters that are required to 
accomplish vectorial transport of salt and water (4, 5, 43). Among those channels and 
transporters, CFTR mediates the movement of bicarbonate as well as chloride and contributes to 
the adjustment of luminal volume and pH (2, 22, 45). Impaired CFTR-mediated anion secretion 
would diminish water movement, decrease bicarbonate secretion, and change vas deferens 
luminal pH. An acid environment is required for sperm to mature as they traverse the 
epididymis. However, an alkaline luminal pH is required to initiate motility and to induce 
fertilizing capacity of sperm cells (8, 30, 36). The critical role of CFTR in the male reproductive 
system has been demonstrated by the magnitude of infertility that is associated with CFTR 
mutations including the high frequency of CBAVD in both severely and mildly affected cystic 
fibrosis patients. Importantly, men with ‘mild’ or hemizygous CFTR gene mutations that have 
intact vasa differentia, often exhibit reduced sperm quality and/or male infertility (10, 23, 42, 
48). Reduced CFTR function would be expected to result in reduced luminal fluid volume and 
reduced pH, which ultimately would have a negative impact on sperm maturation, activation, 
motility and function (33, 46). Our observations that TGF-β1 signaling reduces CFTR expression 
and limits anion secretion suggests that individuals with an elevated level of TGF-β1 may exhibit 
aberrant ion transport across epithelia lining the vas deferens. This, by itself, could lead to 
reduced fertility. Moreover, in CF patients harboring ‘mild’ or hemizygous CFTR mutations, 
greater TGF-β1 signaling may further compromise fertility. 
TGF-β1 modulates ion transport by activating numerous intracellular signaling cascades in 
different types of epithelial cells. TGF-β1 inhibited fluid transport across ATII monolayers 
through a PI3K-dependend mechanism (39). Sodium and fluid transport across ATII monolayers 
were decreased by TGF-β1 through an ERK1/2-dependent mechanism (13). Chloride secretion 
across T84 monolayers was also impaired through a p38 MAPK pathway (18). In PVD9902 
cells, with the observation that TGF-β1 activates TGF-β receptor I, additional experiments were 
conducted to test for mediators of downstream TGF-β1 signaling. Results from initial 
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experiments designed with this goal suggested p38 MAPK as a potential mediator. Therefore, 
subsequent experiments focused on a role for p38 MAPK in the transduction of TGF-β1 
signaling in PVD9902 cells. By applying a selective p38 MAPK signaling pathway inhibitor, 
SB203580, by measuring protein abundance of phosphorylated p38 MAPK, and by using an 
activator of the p38 MAPK signaling pathway, anisomycin, to mimic the effect of TGF-β1, it 
was shown that TGF-β1 activates the p38 MAPK signaling pathway in PVD9902 monolayers. 
Another inhibitor of p38 MAPK, SKF86002, exhibited similar effects as SB203580 (data not 
shown). PVD9902 cells exposed to the combination of SKF86002 and TGF-β1 exhibited a 
higher response to forskolin than cells exposed to TGF-β1 only, suggesting the involvement of 
the p38 MAPK signaling pathway in the effect of TGF-β1. 
In conclusion, the results show that PVD9902 cells exposed to TGF-β1 exhibit reduced cAMP-
stimulated anion secretion. This effect was associated with the activation of TGF-β receptor I 
and the activation of the p38 MAPK signaling pathway. Reductions in mRNA coding for CFTR 
and CFTR protein expression were detected. These observations may have clinical implications 
because high levels of TGF-β1 in close association with vas deferens epithelial cells might 
induce aberrant ion transport, change the luminal environment, and reduce male fertility. 
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Chapter 4 - Summary 
The objective of the current study was to determine the effects of TGF-β1 on vas deferens 
epithelial cells. Primary cultures of freshly isolated vas deferens epithelial cells were used along 
with an immortalized vas deferens epithelial cell line to test for effects of TGF-β1 on 
electrophysiological parameters across and protein expression in the epithelium that lines the vas 
deferens. 
In primary porcine vas deferens epithelial cells, monolayers exposed to TGF-β1 (100 ng/ml, 72 
hours; 100 ng/ml, 24 hours; and 5 ng/ml, 24 hours) exhibited an impaired tight junction barrier as 
indicated by a reduction in Rte and reorganization of occludin and claudin-7. Attenuated 
forskolin-stimulated anion secretion was observed also when cells were exposed to the highest 
concentration of TGF-β1 for the longest period tested. These outcomes suggest that TGF-β1 
impairs the barrier integrity of vas deferens epithelium and reduces the activity of one or more 
components in the ion transport pathway. 
PVD9902 cell monolayers exposed to TGF-β1 at a concentration of 5 ng/ml for 24 hours 
exhibited a significant reduction in response to reagents that initiate signaling through the 
cAMP-mediated pathway, such as forskolin, forskolin/IBMX, and 8-pCPT-cAMP. Attenuated 
anion secretion across PVD9902 monolayers was attributable to reduced permeation through 
CFTR channels, as indicated by a reduced magnitude of current inhibited by CFTR blockers. 
Real-time RT-PCR and immunoblots showed that TGF-β1 reduces the mRNA and protein 
abundance of CFTR. These outcomes suggest that TGF-β1 downregulates CFTR expression and 
limits CFTR-mediated anion secretion. In vivo, such an outcome would change luminal 
composition and pH of vas deferens and would be expected to affect sperm activation, motility, 
and function. 
Both primary porcine vas deferens epithelial cells and PVD9902 cells have been employed to 
determine the effect of TGF-β1. Primary cells may provide biological responses that are closer to 
an in vivo situation. Moreover, primary cultures derived from different porcine donors may 
behave differently due to variations between individuals. Therefore, results from primary 
cultures support inferences to the porcine population. Furthermore, results from our laboratory 
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suggest that similar phenomena would likely be observed within human tissues (1, 4, 7). 
However, the access to primary cultures is inconsistent. PVD9902 cells were derived from a 
single porcine donor and the cells spontaneously immortalized. Therefore, the PVD9902 cell line 
provides a source of materials that is available consistently. PVD9902 cells recapitulate most 
observations of primary cultures and thus observations from PVD9902 cells contribute to the 
characterization of vas deferens epithelia and male reproductive function. In our study, using 
both primary cell cultures and the PVD9902 cell line, the outcomes demonstrate that TGF-β1 
exposure modifies the function of vas deferens epithelia.  
There still exist some apparent differences between primary cultures of vas deferens epithelial 
cells and PVD9902 cells as one assesses the effects of TGF-β1.  
First, TGF-β1 induces a robust reduction of basal Rte in primary cell cultures, but only a slight 
reduction in Rte across PVD9902 monolayers. Basal Rte is determined by paracellular resistance, 
the sum of tight junction resistance and intracellular space resistance, and transcellular 
resistance. We speculate that, compared with primary cultures, PVD9902 cells contain less 
claudin-2, a tight junction protein for which the expression level is reported reciprocal to 
transepithelial resistance (3) and/or higher number of tight junction strands (2). Typically, 
PVD9902 cells exhibit a basal Rte of >8000 Ω cm2, which is higher than the basal Rte of most 
primary cell cultures (~4000 Ω cm2). The high basal transepithelial resistance of PVD9902 may 
reflect characteristics of the cells at the time of their isolation, i.e., the primary porcine vas 
deferens epithelial cell cultures from which PVD9902 cells were derived may have exhibited a 
high innate Rte.  
The second major difference in outcomes is that TGF-β1 induced a more apparent reduction of 
forskolin-stimulated anion secretion in PVD9902 cells compared with primary cell cultures. In 
our proposed cell model (Figure 1.9), chloride and bicarbonate enter vas deferens epithelial cells 
via NKCC and SLC4A4 cotransporters, respectively, across the basolateral membrane and exit 
cells through CFTR channels in the apical membrane. Our data suggest that TGF-β1 exposure 
reduces CFTR expression and thus reduces forskolin-stimulated anion secretion. Attenuated 
forskolin-stimulated anion secretion is not observed in primary cell cultures that are treated with 
the same concentration and duration of TGF-β1. A possible explanation is that freshly isolated 
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vas deferens epithelial cells express CFTR in the apical membrane at higher levels such that 
CFTR is not the factor limiting anion secretion in the presence of maximal cAMP-mediated 
stimulation. The maximum response to forskolin may be limited by the abundance and/or the 
activity of basolateral cotransporters that account for anion entry. It is likely that TGF-β1 also 
reduces CFTR expression in primary cell cultures (unpublished observations from Dr. Vladimir 
Akoyev and myself). However, we speculate that although the abundance of CFTR is down-
regulated, there are still enough CFTR channels in the apical membrane to accommodate all 
anions that enter cells through the basolateral cotransporters. Our data suggest that only when 
primary cell cultures are exposed to a high level of TGF-β1 (e.g., 100 ng/ml for 72 hours), CFTR 
abundance is reduced to an extent that limits anion transport, thereby impairing forskolin-
stimulated anion secretion. To test the possibility of this explanation further, western blot 
experiments can be performed to determine the effect of TGF-β1 on CFTR protein expression in 
primary cultures and to access the effects of selective CFTR blockers in the absence and 
presence of the cytokine. We expect that TGF-β1 exposures at different concentrations and 
durations (e.g., 5 ng/ml for 24 hours; and 100 ng/ml for 72 hours) down-regulate the total CFTR 
expression and the abundance of CFTR in the apical membrane. Moreover, we expect that CFTR 
protein abundance is even lower in primary cultures exposed to a high level of TGF-β1 (e.g., 100 
ng/ml for 72 hours) compared with primary cultures exposed to a lower level of TGF-β1 (e.g., 5 
ng/ml for 24 hours). Therefore, in primary cultures exposed to a lower level of TGF-β1, the 
remaining CFTR is still sufficient for anion secretion while in primary cultures exposed to a high 
level of TGF-β1, the further down-regulated CFTR protein is limiting anion secretion upon 
stimulation. 
TGF-β1 exists mainly in a latent form and also in an active form. The concentration of total 
TGF-β1 in human plasma is ~5 ng/ml (6). The concentration of total TGF-β1 in human semen is 
much higher, reaching 85-238 ng/ml (5, 9). Furthermore, the concentration of active TGF-β1 in 
human semen can be as high as ~2 ng/ml (9). The concentrations of TGF-β1 in the luminal and 
the blood side of vas deferens are unknown. Phosphorylated Smad2/3 can be detected in native 
vas deferens epithelia, suggesting that activated TGF-β1 is present in the male reproductive tract 
(unpublished observations from Dr. Fernando Pierucci-Alves). Some of the PVD9902 cultures 
exposed to the TGF-β receptor blocker showed an elevated basal Isc, suggesting that the 
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PVD9902 cell culture system may include endogenous TGF-β1 that contributes to the regulation 
of ion flux across monolayers. These indirect evidences suggest that a modest level of TGF-β1 
may be secreted and/or activated by vas deferens epithelial cells in culture to regulate cell 
function, although the possibility that there is some amount of TGF-β1 in serum in the cell 
culture media has not been ruled out. Genetic polymorphisms of TGF-β1 likely affect the basal 
level of TGF-β1 in the lumen and on the blood side of vas deferens. Pathological conditions, 
such as inflammation may upregulate of TGF-β1 expression or activation and increase TGF-β1 
signaling in the vas deferens. Therefore, individuals with lower basal TGF-β1 signaling might be 
less prone to dysfunction of male reproductive tract while individuals with a TGF-β1 ‘high 
producer’ phenotype might be predisposed to subfertility and with a second insult such as 
reduced lumen pH and reduced fluid secretion are likely to exhibit more severe symptoms. 
TGF-β1 exposure modulates the barrier function of and/or anion secretion across vas deferens 
epithelial cells. These TGF-β1-induced changes may modify the ionic composition, pH and 
volume of fluid in the vas deferens lumen. Under normal conditions without stimulation, sperm 
in the vas deferens lumen are thought to be exposed to an acidic environment and thus are kept in 
a quiescent state (8). TGF-β1 exposure disrupts tight junctions between vas deferens epithelial 
cells, which may lead to mixing of luminal and interstitial fluid, resulting in an increased luminal 
pH in resting conditions. In the more alkaline environment, some sperm cells could be activated, 
which would reduce long term viability. When stimulation occurs in conjunction with sexual 
activity, intracellular cAMP generation of vas deferens epithelial cells is elevated, which 
activates CFTR and stimulates the vectorial transport of anions and fluid into the lumen. Fluid 
transport increases the volume of vas deferens luminal fluid while bicarbonate secretion 
contributes to an alkaline luminal pH. In healthy conditions, rapid alkalization of the luminal 
fluid would increase sperm motility and favor their fertilizing potential. Again, ducts exposed to 
TGF-β1 would be expected to have elevated resting pH due to compromised tight junctions and 
reduced numbers of viable sperms. Additionally, TGF-β1 exposure would downregulate CFTR 
channel expression and would diminish the ability of these ducts to respond to stimulation with 
anion and fluid secretion. Epithelial cell exposed to TGF-β1 would be unable to alkalinize the 
lumen to the extent that occurs in healthy ducts. Thus, under stimulated conditions, sperm cells 
are likely exposed to a more acidic vas deferens luminal environment, leading to a state of 
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reduced sperm motility. Male patients with ‘mild’ CFTR mutations or male carriers of single 
mutant CFTR gene express less functional CFTR, which may contribute to attenuated anion 
secretion at the outset. In these individuals, TGF-β1 exposure would be expected to reduce 
CFTR expression, further compromise the electrophysiological parameters of vas deferens 
epithelium, modify the luminal microenvironment in vas deferens, and thus reduce male fertility 
or induce male infertility. 
In summary, these outcomes, using both primary porcine vas deferens cells and cultured 
PVD9902 cells, suggest that TGF-β1 modulates the electrophysiological parameters of vas 
deferens epithelia. These observations have clinical implications as vas deferens epithelia would 
modify dynamically regulate the luminal environment to which sperm are exposed, and thus 
affect male fertility. Taken together, our results suggest a novel mechanism to account for 
subfertility and infertility in cystic fibrosis patients harboring ‘mild’ mutations and in carriers of 
a mutated CFTR allele. This novel mechanism incorporates the impact of TGF-β1 expression or 
epithelial function in the context of reduced CFTR expression. 
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